<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="64a057e0-ddd4-49be-b9f6-3d4fb828ea64"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use DAYTRANA<sup>®</sup> safely and effectively. See full prescribing information for DAYTRANA.</content>
      <br/>
      <br/>
      <content styleCode="bold">DAYTRANA<sup>®</sup> (methylphenidate transdermal system), CII </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2006</content>
   </title>
   <effectiveTime value="20250527"/>
   <setId root="2c312c31-3198-4775-91ab-294e0b4b9e7f"/>
   <versionNumber value="28"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="166888268"/>
            <name>Noven Therapeutics, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="148585441"/>
                  <name>Noven Pharmaceuticals, Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="148585441"/>
                        <name>Noven Pharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68968-5552" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68968-5553" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68968-5554" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68968-5555" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68968-5552" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68968-5553" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68968-5554" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68968-5555" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="33458544-c780-472d-b430-7665170dac48"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20230608"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68968-5552" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Daytrana
</name>
                        <formCode code="C42968" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>methylphenidate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="h" value="9"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="9" unit="h"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C82332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="30" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68968-5552-3" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20060406"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021514" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060406"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38305" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRANSDERMAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68968-5553" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Daytrana
</name>
                        <formCode code="C42968" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>methylphenidate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="h" value="9"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="9" unit="h"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C82332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="30" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68968-5553-3" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20060406"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021514" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060406"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38305" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRANSDERMAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68968-5554" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Daytrana
</name>
                        <formCode code="C42968" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>methylphenidate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="h" value="9"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="9" unit="h"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C82332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="30" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68968-5554-3" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20060406"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021514" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060406"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38305" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRANSDERMAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68968-5555" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Daytrana
</name>
                        <formCode code="C42968" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>methylphenidate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="h" value="9"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="9" unit="h"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C82332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PATCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="30" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68968-5555-3" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20060406"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021514" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060406"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38305" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRANSDERMAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRBlackBox">
               <id root="b5f8fb00-8c22-4b4c-b17a-ec1cae7a0f8a"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
            WARNING: ABUSE, MISUSE, AND ADDICTION
          </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">DAYTRANA has a high potential for abuse and misuse, which can lead to the development of substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#splSectionPLROverdose">10</linkHtml>)]</content>
                  , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. 
                </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before prescribing DAYTRANA, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout DAYTRANA treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection13">5.1</linkHtml>) and Drug Abuse and Dependence (<linkHtml href="#splSectionPLRAbuse">9.2</linkHtml>)]</content> . </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250602"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: ABUSE, MISUSE, AND ADDICTION</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="bold">See full prescribing information for complete boxed warning</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">DAYTRANA has high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death (<linkHtml href="#splSection13">5.1</linkHtml>, <linkHtml href="#splSectionPLRAbuse">9.2</linkHtml>, <linkHtml href="#splSectionPLROverdose">10</linkHtml>):</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Before prescribing DAYTRANA, assess each patient’s risk for abuse, misuse, and addiction.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L85b21407-e200-40c8-874f-3354de746747">
               <id root="00551796-364d-43b2-a56d-6589be51585c"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <text/>
               <effectiveTime value="20250602"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <tbody>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#splSection5">2.3</linkHtml>)</td>
                                 <td align="right">10/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRIndicationsUsage">
               <id root="d1b893c7-ccff-4681-974b-433ff22235b0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
              DAYTRANA (methylphenidate transdermal system) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
            </paragraph>
               </text>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>DAYTRANA is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. (<linkHtml href="#splSectionPLRIndicationsUsage">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRDosageAdministration">
               <id root="3779ed24-601f-4360-9356-71f1083466e3"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended starting dose for patients new to or converting from another formulation of methylphenidate is 10 mg. (<linkHtml href="#splSection4">2.2</linkHtml>)</item>
                           <item>DAYTRANA should be applied to the hip area (using alternating sites) 2 hours before an effect is needed and should be removed 9 hours after application. DAYTRANA may be removed earlier than 9 hours if a shorter duration of effect is desired or late day side effects appear. (<linkHtml href="#splSection4">2.2</linkHtml>, <linkHtml href="#splSection5">2.3</linkHtml>)</item>
                           <item>Dosage should be titrated to effect. Dose titration, final dosage, and wear time should be individualized according to the needs and response of the patient. (<linkHtml href="#splSection4">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="splSection3">
                     <id root="6132eed8-2923-4199-9866-992eab6cc3cf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Pretreatment Screening</title>
                     <text>
                        <paragraph>Prior to treating patients with DAYTRANA, assess:</paragraph>
                        <list listType="unordered">
                           <item>for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection14">5.2</linkHtml>)]</content> .</item>
                           <item>the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating DAYTRANA <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#L03491982-bb93-48f5-bdbf-c85f1acf757e">5.15</linkHtml>)]</content> .</item>
                        </list>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection4">
                     <id root="e43ed0b5-f1c7-4590-91a1-c486ba2d6251"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage</title>
                     <text>
                        <paragraph>It is recommended that DAYTRANA be applied to the hip area 2 hours before an effect is needed and should be removed 9 hours after application. Dosage should be titrated to effect. The recommended dose titration schedule is shown in the table below. Dose titration, final dosage, and wear time should be individualized according to the needs and response of the patient.</paragraph>
                        <table ID="i336c658e-fa82-497d-8862-32b3194b1cde" width="800">
                           <colgroup>
                              <col width="40%" align="center"/>
                              <col width="15%" align="center"/>
                              <col width="15%" align="center"/>
                              <col width="15%" align="center"/>
                              <col width="15%" align="center"/>
                           </colgroup>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="5" align="left">
                                    <paragraph styleCode="First Footnote">*Nominal <content styleCode="italics">in vivo</content> delivery rate in children and adolescents when applied to the hip, based on a 9-hour wear period.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule" colspan="5" align="left">
                                    <content styleCode="bold">Table 1      DAYTRANA - Recommended Titration Schedule (Patients New to Methylphenidate)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" colspan="5" align="center">Upward Titration, if Response is Not Maximized</td>
                              </tr>
                              <tr>
                                 <td align="center"/>
                                 <td align="center">Week 1</td>
                                 <td align="center">Week 2</td>
                                 <td align="center">Week 3</td>
                                 <td align="center">Week 4</td>
                              </tr>
                              <tr>
                                 <td align="center">Transdermal System Size</td>
                                 <td align="center">12.5 cm <sup>2</sup>
                                 </td>
                                 <td align="center">18.75 cm <sup>2</sup>
                                 </td>
                                 <td align="center">25 cm <sup>2</sup>
                                 </td>
                                 <td align="center">37.5 cm <sup>2</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">Nominal Delivered Dose* (mg/9 hours)</td>
                                 <td align="center">10 mg</td>
                                 <td align="center">15 mg</td>
                                 <td align="center">20 mg</td>
                                 <td align="center">30 mg</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" align="center">Delivery Rate*</td>
                                 <td styleCode="Botrule" align="center">(1.1 mg/hr)*</td>
                                 <td styleCode="Botrule" align="center">(1.6 mg/hr)*</td>
                                 <td styleCode="Botrule" align="center">(2.2 mg/hr)*</td>
                                 <td styleCode="Botrule" align="center">(3.3 mg/hr)*</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Patients converting from another formulation of methylphenidate should follow the above titration schedule due to differences in bioavailability of DAYTRANA compared to other products.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection5">
                     <id root="db6073de-5dbd-4cc6-8926-a5b74b0710e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Application</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">The parent or caregiver should be encouraged to use the administration chart included with each carton of DAYTRANA to monitor application and removal time, and method of disposal. It is recommended that parents or caregivers apply and remove the transdermal system for children; responsible adolescents may apply or remove the transdermal system themselves if appropriate. If a transdermal system was removed without the parent or caregiver's knowledge, or if a transdermal system is missing from the tray, the parent or caregiver should be encouraged to ask the child when and how the transdermal system was removed. The Medication Guide includes a timetable to calculate when to remove DAYTRANA, based on the 9-hour application time.</content>
                        </paragraph>
                        <paragraph>The adhesive side of DAYTRANA should be placed on a clean, dry area of the hip. The area selected should not be oily, damaged, or irritated. Apply DAYTRANA to the hip area avoiding the waistline, since clothing may cause the transdermal system to rub off. When applying the transdermal system the next morning, place on the opposite hip at a new site if possible.</paragraph>
                        <paragraph>If patients or caregivers experience difficulty separating the transdermal system from the release liner or observe transfer of adhesive to the liner, tearing and/or other damage to the transdermal system during removal from the liner, the transdermal system should be discarded and a new transdermal system should be applied. Patients or caregivers should inspect the release liner to ensure that no adhesive containing medication has transferred to the liner. If adhesive transfer has occurred, the transdermal system should be discarded. Refer to the <content styleCode="italics">Instructions for Use</content> for recommendations for discarding used DAYTRANA.</paragraph>
                        <paragraph>DAYTRANA should be applied immediately after opening the individual pouch and removing the protective liner. Do not use if the individual pouch seal is broken or if the transdermal system appears to be damaged. Do not cut transdermal systems. Only intact transdermal systems should be applied. The transdermal system should then be pressed firmly in place with the palm of the hand for approximately 30 seconds, making sure that there is good contact of the transdermal system with the skin, especially around the edges. Exposure to water during bathing, swimming, or showering can affect transdermal system adherence. DAYTRANA should not be applied or re-applied with dressings, tape, or other common adhesives. In the event that a transdermal system does not fully adhere to the skin upon application, or becomes partially or fully detached during wear time, the transdermal system should be discarded and a new transdermal system may be applied at a different site. The total recommended wear time for that day should remain 9 hours regardless of the number of transdermal systems used.</paragraph>
                        <paragraph>All patients should be advised to avoid exposing the DAYTRANA application site to direct external heat sources, such as hair dryers, heating pads, electric blankets, heated water beds, etc., while wearing the transdermal system<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#splSection19">5.10</linkHtml>)]</content>. When heat is applied to DAYTRANA after transdermal system application, both the rate and the extent of absorption are significantly increased. The temperature-dependent increase in methylphenidate absorption can be greater than 2-fold <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#splSectionPLRPharmacokinetics">12.3</linkHtml>)]</content>. This increased absorption can be clinically significant and result in overdose of methylphenidate <content styleCode="italics">[see Overdosage (<linkHtml href="#splSectionPLROverdose">10</linkHtml>)]</content>.</paragraph>
                        <paragraph>DAYTRANA should not be stored in refrigerators or freezers.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection6">
                     <id root="3de0ba6d-5c1e-4c50-9624-8fb75c355a2e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Removal of DAYTRANA</title>
                     <text>
                        <paragraph>DAYTRANA should be peeled off slowly. If necessary, transdermal system removal may be facilitated by gently applying an oil-based product (i.e., petroleum jelly, olive oil, or mineral oil) to the transdermal system edges, gently working the oil underneath the transdermal system edges. If any adhesive remains on the skin following transdermal system removal, an oil-based product may be applied to transdermal system sites in an effort to gently loosen and remove any residual adhesive that remains following transdermal system removal.</paragraph>
                        <paragraph>In the unlikely event that a transdermal system remains tightly adhered despite these measures, the patient or caregiver should contact the physician or pharmacist. Nonmedical adhesive removers and acetone-based products (i.e., nail polish remover) should not be used to remove DAYTRANA or adhesive.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection7">
                     <id root="fa5cac2d-acf7-49f7-8f3c-ebcce40dc777"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dose/Wear Time Reduction and Discontinuation</title>
                     <text>
                        <paragraph>DAYTRANA may be removed earlier than 9 hours if a shorter duration of effect is desired or late day side effects appear. Plasma concentrations of <content styleCode="italics">d</content>-methylphenidate generally begin declining when the transdermal system is removed, although absorption may continue for several hours. Individualization of wear time may help manage some of the side effects caused by methylphenidate. If aggravation of symptoms or other adverse events occur, the dosage or wear time should be reduced, or, if necessary, the drug should be discontinued. Residual methylphenidate remains in used transdermal systems when worn as recommended.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRDosageFormsStrength">
               <id root="7b9da93e-99d3-4897-b415-ab7a3c9ff951"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORM AND STRENGTHS</title>
               <text>
                  <paragraph>Four dosage strengths are available:</paragraph>
                  <table ID="i2f48938a-96f5-4342-8436-c4f10e342690" width="800">
                     <colgroup>
                        <col width="30%" align="center"/>
                        <col width="20%" align="center"/>
                        <col width="20%" align="center"/>
                        <col width="30%" align="center"/>
                     </colgroup>
                     <tfoot>
                        <tr>
                           <td colspan="4" align="left">
                              <paragraph styleCode="First Footnote">*Nominal <content styleCode="italics">in vivo</content> delivery rate in children and adolescents when applied to the hip, based on a 9-hour wear period.</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule" align="left">
                              <content styleCode="bold">Nominal Dose Delivered <br/>(mg) Over 9 Hours* </content>
                           </td>
                           <td styleCode="Botrule" align="left">
                              <content styleCode="bold">Dosage Rate* <br/>(mg/hr) </content>
                           </td>
                           <td styleCode="Botrule" align="left">
                              <content styleCode="bold">Transdermal System Size <br/>(cm <sup>2</sup>) </content>
                           </td>
                           <td styleCode="Botrule" align="left">
                              <content styleCode="bold">Methylphenidate <br/>Content per Transdermal System (mg) </content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center">10</td>
                           <td align="center">1.1</td>
                           <td align="center">12.5</td>
                           <td align="center">27.5</td>
                        </tr>
                        <tr>
                           <td align="center">15</td>
                           <td align="center">1.6</td>
                           <td align="center">18.75</td>
                           <td align="center">41.3</td>
                        </tr>
                        <tr>
                           <td align="center">20</td>
                           <td align="center">2.2</td>
                           <td align="center">25</td>
                           <td align="center">55</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="center">30</td>
                           <td styleCode="Botrule" align="center">3.3</td>
                           <td styleCode="Botrule" align="center">37.5</td>
                           <td styleCode="Botrule" align="center">82.5</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Transdermal system: 10mg/9 hours (1.1 mg/hr), 15mg/9 hours (1.6 mg/hr), 20mg/9 hours (2.2 mg/hr), 30mg/9 hours (3.3 mg/hr) (<linkHtml href="#splSectionPLRDosageFormsStrength">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRContraindications">
               <id root="b573177b-f2f9-4320-8a40-96b5db8cf683"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text/>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Known hypersensitivity to methylphenidate (<linkHtml href="#splSection8">4.1</linkHtml>)</item>
                           <item>Patients currently using or within 2 weeks of using an MAO inhibitor (<linkHtml href="#splSection12">4.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="splSection8">
                     <id root="5a50a3e4-d43e-4853-ae7a-a1a8827c9826"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                4.1 Hypersensitivity to Methylphenidate
              </title>
                     <text>
                        <paragraph>DAYTRANA is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product (polyester/ethylene vinyl acetate laminate film backing, acrylic adhesive, silicone adhesive, and fluoropolymer-coated polyester) <content styleCode="italics">[see Description (<linkHtml href="#splSectionPLRDescription">11</linkHtml>)] </content>
                  .
                </paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection12">
                     <id root="9c099351-284d-4322-8f2a-cefb1b0f6aa7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                4.2 Monoamine Oxidase Inhibitors
              </title>
                     <text>
                        <paragraph>
                  DAYTRANA is contraindicated during treatment with monoamine oxidase inhibitors, and within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor (hypertensive crises may result).
                </paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRWarnings">
               <id root="fac82980-1b32-4288-a81c-6b613a4d3928"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Risks to Patients with Serious Cardiac Disease: Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. (<linkHtml href="#splSection14">5.2</linkHtml>)</item>
                           <item>Increased Blood Pressure and Heart Rate: Monitor blood pressure and pulse. (<linkHtml href="#splSection15">5.3</linkHtml>)</item>
                           <item>Psychiatric Adverse Reactions: Prior to initiating DAYTRANA, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing DAYTRANA. (<linkHtml href="#splSection0504">5.4</linkHtml>)</item>
                           <item>Seizures: Stimulants may lower the convulsive threshold. Discontinue in the presence of seizures. (<linkHtml href="#splSection16">5.5</linkHtml>)</item>
                           <item>Priapism: If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention. (<linkHtml href="#b8b-0800200c9a66-5-5">5.6</linkHtml>)</item>
                           <item>Peripheral Vasculopathy, including Raynaud’s phenomenon: Careful observation for digital changes is necessary during DAYTRANA treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy. (<linkHtml href="#AS560">5.7</linkHtml>)</item>
                           <item>Long-Term Suppression of Growth in Pediatric Patients: Closely monitor (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted. (<linkHtml href="#splSection18">5.8</linkHtml>)</item>
                           <item>Chemical Leukoderma: DAYTRANA use may result in a persistent loss of skin pigmentation at and around the application site. Loss of pigmentation, in some cases, has been reported at other sites distant from the application site. Monitor for signs of skin depigmentation. Discontinue DAYTRANA if it occurs. (<linkHtml href="#splSection17">5.9</linkHtml>)</item>
                           <item>Contact Sensitization: Use of DAYTRANA may lead to contact sensitization. Treatment should be discontinued if contact sensitization is suspected. Erythema is commonly seen with use of DAYTRANA and is not by itself an indication of sensitization. However, contact sensitization should be suspected if erythema is accompanied by evidence of a more intense local reaction (edema, papules, vesicles) that does not significantly improve within 48 hours or spreads beyond the transdermal system site. (<linkHtml href="#splSection19">5.10</linkHtml>)</item>
                           <item>External Heat: Patients should be advised to avoid exposing the DAYTRANA application site to direct external heat sources. When heat is applied to DAYTRANA after application, both the rate and extent of absorption are significantly increased. (<linkHtml href="#splSection20">5.11</linkHtml>)</item>
                           <item>Hematologic monitoring: Periodic CBC, differential, and platelet counts are advised during prolonged therapy. (<linkHtml href="#La1fdb6e8-fdd2-4775-8cda-8cd0c8d88803">5.12</linkHtml>)</item>
                           <item>Acute Angle Closure Glaucoma: DAYTRANA-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist. (<linkHtml href="#L063c9c84-4a2a-45e6-936b-41aa2c324d66">5.13</linkHtml>)</item>
                           <item>Increased Intraocular Pressure (IOP) and Glaucoma: Prescribe DAYTRANA to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor patients with a history of increased IOP or open angle glaucoma. (<linkHtml href="#Lc0619838-7850-4b18-b7d3-d7a767cf7b44">5.14</linkHtml>)</item>
                           <item>Motor and Verbal Tics and Worsening of Tourette’s Syndrome: Before initiating DAYTRANA, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor patients for the emergence or worsening of tics or Tourette’s syndrome. Discontinue treatment if clinically appropriate. (<linkHtml href="#L03491982-bb93-48f5-bdbf-c85f1acf757e">5.15</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="splSection13">
                     <id root="24989580-03f2-427f-996b-9d5fa34fd5cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                5.1 Abuse, Misuse, and Addiction
              </title>
                     <text>
                        <paragraph>DAYTRANA has a high potential for abuse and misuse. The use of DAYTRANA exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. DAYTRANA can be diverted for non-medical use into illicit channels or distribution <content styleCode="italics">[see Drug Abuse and Dependence (<linkHtml href="#splSectionPLRAbuse">9.2</linkHtml>)]</content>. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#splSectionPLROverdose">10</linkHtml>)]</content>
                  , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
                </paragraph>
                        <paragraph>
                  Before prescribing DAYTRANA, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their caregivers or families about these risks. Advise patients to store DAYTRANA in a safe place, preferably locked, and instruct patients to not give DAYTRANA to anyone else. Throughout DAYTRANA treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
                </paragraph>
                        <paragraph>
                  DAYTRANA has special disposal instructions. Instruct patients to find a take back location to dispose of unused or expired DAYTRANA. If a take back program is unavailable, instruct them to:
                </paragraph>
                        <list listType="ordered">
                           <item>
                    Remove DAYTRANA from its pouch, separate it from its liner, fold it in half with the adhesive sides touching each other, and immediately flush the used transdermal system down the toilet, and
                  </item>
                           <item>
                    Place the pouch and liner in a container, close the container, and throw out the container in the trash (advise patients not to flush the pouch and liner down the toilet).
                  </item>
                        </list>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection14">
                     <id root="c3de0d21-fc54-4b8d-b359-139a7092783c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                5.2 Risks to Patients with Serious Cardiac Disease
              </title>
                     <text>
                        <paragraph>
                  Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage.
                </paragraph>
                        <paragraph>
                  Avoid DAYTRANA use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.
                </paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection15">
                     <id root="e19b4ddc-5f0f-4978-9fd3-6580feb46b42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                5.3 Increased Blood Pressure and Heart Rate
              </title>
                     <text>
                        <paragraph>
                  CNS stimulants may cause an increase in blood pressure (mean increase approximately 2 to 4 mmHg) and heart rate (mean increase approximately 3 to 6 bpm). Some patients may have larger increases.
                </paragraph>
                        <paragraph>
                  Monitor all DAYTRANA-treated patients for hypertension and tachycardia.
                </paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection0504">
                     <id root="96caee79-8204-4e3b-ba4e-3cc5c090fec6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Psychiatric Adverse Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline"> Exacerbation of Pre-Existing Psychosis</content>
                        </paragraph>
                        <paragraph>
                  CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.
                </paragraph>
                        <paragraph>
                           <content styleCode="underline"> Induction of a Manic Episode in Patients with Bipolar Disease</content>
                        </paragraph>
                        <paragraph>
                  CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating DAYTRANA treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).
                </paragraph>
                        <paragraph>
                           <content styleCode="underline"> New Psychotic or Manic Symptoms</content>
                        </paragraph>
                        <paragraph>
                  CNS stimulants, at the recommended dosages, may cause psychotic or manic symptoms, (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients compared with 0% of placebo-treated patients. If such symptoms occur, consider discontinuing DAYTRANA.
                </paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection16">
                     <id root="c3a1229f-3868-4940-8585-a8547ebe3cf3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Seizures</title>
                     <text>
                        <paragraph>There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="b8b-0800200c9a66-5-5">
                     <id root="0fd3a750-ca45-4a89-b17c-fecfc4070c21"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Priapism</title>
                     <text>
                        <paragraph>Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate use in both adult and pediatric male patients. Although priapism was not reported with methylphenidate initiation, it developed after some time on the methylphenidate, often subsequent to an increase in dosage. Priapism also occurred during methylphenidate withdrawal (drug holidays or during discontinuation).</paragraph>
                        <paragraph>DAYTRANA-treated patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="AS560">
                     <id root="92750133-7409-400a-9672-6f822667dbb2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Peripheral Vasculopathy, including Raynaud’s phenomenon</title>
                     <text>
                        <paragraph>Stimulant medications, including DAYTRANA, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports and at therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant.</paragraph>
                        <paragraph>Careful observation for digital changes is necessary during DAYTRANA treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for DAYTRANA-treated patients who develop signs or symptoms of peripheral vasculopathy.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection18">
                     <id root="7ad82d2f-f3ce-40fc-b75d-19ecc13ce031"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Long-Term Suppression of Growth in Pediatric Patients</title>
                     <text>
                        <paragraph>
                  CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.
                </paragraph>
                        <paragraph>
                  Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that pediatric patients who received methylphenidate for 7 days per week throughout the year had a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this development period.
                </paragraph>
                        <paragraph>
                  Closely monitor growth (weight and height) in DAYTRANA-treated pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted.
                </paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection17">
                     <id root="a75e3b87-9305-486a-ad3d-a53d0a505ab7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Chemical Leukoderma</title>
                     <text>
                        <paragraph>DAYTRANA use may result in a persistent loss of skin pigmentation at and around the application site. Loss of pigmentation, in some cases, has been reported at other sites distant from the application site. Chemical leukoderma can mimic the appearance of vitiligo, particularly when the loss of skin pigmentation involves areas distant from the application site. Individuals with a history of vitiligo and/or a family history of vitiligo may be more at risk. Skin depigmentation may persist even after DAYTRANA use is discontinued. Monitor for signs of skin depigmentation, and advise patients to immediately inform their healthcare provider if changes in skin pigmentation occur. Discontinue use of the DAYTRANA in patients with chemical leukoderma.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection19">
                     <id root="71840817-bb9e-47c4-bf1b-cb664fbc1465"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Contact Sensitization</title>
                     <text>
                        <paragraph>In an open-label study of 305 subjects conducted to characterize dermal reactions in children with ADHD treated with DAYTRANA using a 9-hour wear time, one subject (0.3%) was confirmed by patch testing to be sensitized to methylphenidate (allergic contact dermatitis). This subject experienced erythema and edema at DAYTRANA application sites with concurrent urticarial lesions on the abdomen and legs resulting in treatment discontinuation. This subject was not transitioned to oral methylphenidate.</paragraph>
                        <paragraph>Use of DAYTRANA may lead to contact sensitization. DAYTRANA should be discontinued if contact sensitization is suspected. Erythema is commonly seen with use of DAYTRANA and is not by itself an indication of sensitization. However, contact sensitization should be suspected if erythema is accompanied by evidence of a more intense local reaction (edema, papules, vesicles) that does not significantly improve within 48 hours or spreads beyond the transdermal system site. Confirmation of a diagnosis of contact sensitization (allergic contact dermatitis) may require further diagnostic testing.</paragraph>
                        <paragraph>Patients sensitized from use of DAYTRANA, as evidenced by development of an allergic contact dermatitis, may develop systemic sensitization or other systemic reactions if methylphenidate-containing products are taken via other routes, e.g., orally. Manifestations of systemic sensitization may include a flare-up of previous dermatitis or of prior positive patch-test sites, or generalized skin eruptions in previously unaffected skin. Other systemic reactions may include headache, fever, malaise, arthralgia, diarrhea, or vomiting. No cases of systemic sensitization have been observed in clinical trials of DAYTRANA.</paragraph>
                        <paragraph>Patients who develop contact sensitization to DAYTRANA and require oral treatment with methylphenidate should be initiated on oral medication under close medical supervision. It is possible that some patients sensitized to methylphenidate by exposure to DAYTRANA may not be able to take methylphenidate in any form.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection20">
                     <id root="2d961440-d5ce-4b0b-9817-c5b331af322f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Patients Using External Heat</title>
                     <text>
                        <paragraph>Patients should be advised to avoid exposing the DAYTRANA application site to direct external heat sources, such as hair dryers, heating pads, electric blankets, heated water beds, etc., while wearing the transdermal system. When heat is applied to DAYTRANA after application, both the rate and extent of absorption are significantly increased. The temperature-dependent increase in methylphenidate absorption can be greater than 2-fold <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#splSectionPLRPharmacokinetics">12.3</linkHtml>)]</content>. This increased absorption can be clinically significant and can result in overdose of methylphenidate <content styleCode="italics">[see Overdosage (<linkHtml href="#splSectionPLROverdose">10</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="La1fdb6e8-fdd2-4775-8cda-8cd0c8d88803">
                     <id root="ac7bdc32-84dd-4937-9bf1-36359c96ba5b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Hematologic Monitoring</title>
                     <text>
                        <paragraph>Periodic CBC, differential, and platelet counts are advised during prolonged therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="L063c9c84-4a2a-45e6-936b-41aa2c324d66">
                     <id root="c150b369-fc4d-4a10-ba5b-bf6951159aa5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                5.13 Acute Angle Closure Glaucoma
              </title>
                     <text>
                        <paragraph>
                  There have been reports of angle closure glaucoma associated with methylphenidate treatment.
                </paragraph>
                        <paragraph>
                  Although the mechanism is not clear, DAYTRANA-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist.
                </paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc0619838-7850-4b18-b7d3-d7a767cf7b44">
                     <id root="5aa5aa03-8e62-40ba-a2cd-50113e17fc70"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                5.14 Increased Intraocular Pressure and Glaucoma
              </title>
                     <text>
                        <paragraph>
                  There have been reports of an elevation of intraocular pressure (IOP) associated with methylphenidate treatment <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#splSection37">6.2</linkHtml>)]</content>
                  .
                </paragraph>
                        <paragraph>
                  Prescribe DAYTRANA to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor DAYTRANA-treated patients with a history of abnormally increased IOP or open angle glaucoma.
                </paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="L03491982-bb93-48f5-bdbf-c85f1acf757e">
                     <id root="cb536166-7d8f-4cdf-a3ae-b99d895b2dd3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                5.15 Motor and Verbal Tics, and Worsening of Tourette’s Syndrome
              </title>
                     <text>
                        <paragraph>
                  CNS stimulants, including methylphenidate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#splSection37">6.2</linkHtml>)]</content>
                  .
                </paragraph>
                        <paragraph>
                  Before initiating DAYTRANA, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor DAYTRANA-treated patients for the emergence or worsening of tics or Tourette’s syndrome, and discontinue treatment if clinically appropriate.
                </paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRAdverseReactions">
               <id root="a7cabad7-22f9-47bd-87f6-c6247c6cd09f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Detailed information on serious and adverse reactions of particular importance is provided in the <content styleCode="italics">
                        <linkHtml href="#splSectionPLRBlackBox"> Boxed Warning </linkHtml>
                     </content> and <content styleCode="italics">Warnings and Precautions</content> (<linkHtml href="#splSectionPLRWarnings">5</linkHtml>) sections:</paragraph>
                  <list listType="unordered">
                     <item>Abuse, Misuse, and Addiction <content styleCode="italics">[see <linkHtml href="#splSectionPLRBlackBox">Boxed Warning</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Hypersensitivity to Methylphenidate <content styleCode="italics">[</content>
                        <content styleCode="italics">see Contraindications (<linkHtml href="#splSection8">4.1</linkHtml>)</content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Monoamine Oxidase Inhibitors <content styleCode="italics">[</content>
                        <content styleCode="italics">see Contraindications (<linkHtml href="#splSection12">4.2</linkHtml>)</content> and <content styleCode="italics">Drug Interactions (<linkHtml href="#splSection23">7.1</linkHtml>)</content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Risks to Patients with Serious Cardiac Disease <content styleCode="italics">[</content>
                        <content styleCode="italics">see Warnings and Precautions (<linkHtml href="#splSection14">5.2</linkHtml>)]</content>
                     </item>
                     <item>Increased Blood Pressure and Heart Rate <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection15">5.3</linkHtml>)]</content>
                     </item>
                     <item>Psychiatric Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection0504">5.4</linkHtml>)]</content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection16">5.5</linkHtml>)]</content>
                     </item>
                     <item>Priapism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#b8b-0800200c9a66-5-5">5.6</linkHtml>)]</content>
                     </item>
                     <item>Peripheral Vasculopathy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#AS560">5.7</linkHtml>)]</content>
                     </item>
                     <item>Long-Term Suppression of Growth in Pediatric Patients<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#splSection18">5.8</linkHtml>)]</content>
                     </item>
                     <item>Chemical Leukoderma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection17">5.9</linkHtml>)]</content>
                     </item>
                     <item>Contact Sensitization<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#splSection19">5.10</linkHtml>)]</content>
                     </item>
                     <item>External Heat <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection20">5.11</linkHtml>)]</content>
                     </item>
                     <item>Hematologic Monitoring <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#La1fdb6e8-fdd2-4775-8cda-8cd0c8d88803">5.12</linkHtml>)]</content>
                     </item>
                     <item>Acute Angle Closure Glaucoma<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#L063c9c84-4a2a-45e6-936b-41aa2c324d66">5.13</linkHtml>)]</content>
                     </item>
                     <item>Increased Intraocular Pressure and Glaucoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Lc0619838-7850-4b18-b7d3-d7a767cf7b44">5.14</linkHtml>)]</content>
                     </item>
                     <item>Motor and Verbal Tics, and Worsening of Tourette’s Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#L03491982-bb93-48f5-bdbf-c85f1acf757e">5.15</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pediatric patients (ages 6 to 12 years): The most commonly (≥5% and twice the rate of placebo) reported adverse reactions in pediatric patients ages 6 to 12 years included appetite decreased, insomnia, nausea, vomiting, weight decreased, tic, affect lability, and anorexia. (<linkHtml href="#splSection35">6.1</linkHtml>)</item>
                           <item>Pediatric patients (ages 13 to 17 years): The most commonly (≥5% and twice the rate of placebo) reported adverse reactions in pediatric patients ages 13 to 17 years included appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia. The majority of subjects in these trials had erythema at the application site. (<linkHtml href="#splSection35">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Noven Therapeutics, LLC at 1-800-455-8070 or FDA at 1-800-FDA-1088 or <content styleCode="underline">www.fda.gov/medwatch</content>. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="splSection35">
                     <id root="22fd29a4-b2b2-4a72-9ffb-13ed0d8eb29d"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The most commonly reported (frequency ≥ 5% and twice the rate of placebo) adverse reactions in a controlled trial in children aged 6-12 included appetite decreased, insomnia, nausea, vomiting, weight decreased, tic, affect lability, and anorexia. The most commonly reported (frequency ≥ 5% and twice the rate of placebo) adverse reactions in a controlled trial in adolescents aged 13-17 were appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia<content styleCode="italics"> [see Adverse Reactions (<linkHtml href="#splSection35">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>The most common (≥ 2% of subjects) adverse reaction associated with discontinuations in double-blind clinical trials in children or adolescents was application site reactions <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#splSection35">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>The overall DAYTRANA development program included exposure to DAYTRANA in a total of 2,152 participants in clinical trials, including 1,529 children aged 6-12, 223 adolescents aged 13-17, and 400 adults. The 1,752 child and adolescent subjects aged 6-17 years were evaluated in 10 controlled clinical studies, 7 open-label clinical studies, and 5 clinical pharmacology studies. In a combined studies pool of children using DAYTRANA with a wear time of 9 hours, 212 subjects were exposed for ≥ 6 months and 115 were exposed for ≥ 1 year; 85 adolescents have been exposed for ≥ 6 months. Most patients studied were exposed to DAYTRANA transdermal system sizes of 12.5 cm<sup>2</sup>, 18.75 cm<sup>2</sup>, 25 cm<sup>2</sup> or 37.5 cm<sup>2</sup>, with a wear time of 9 hours.</paragraph>
                        <paragraph>In the data presented below, the adverse reactions reported during exposure were obtained primarily by general inquiry at each visit, and were recorded by the clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of events into a smaller number of standardized event categories.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Adverse Reactions in Clinical Studies with Discontinuation of Treatment</content>
                        </paragraph>
                        <paragraph>In a 7-week double-blind, parallel-group, placebo-controlled study in children with ADHD conducted in the outpatient setting, 7.1% (7/98) of patients treated with DAYTRANA discontinued due to adverse events compared with 1.2% (1/85) receiving placebo. The most commonly reported (≥ 1% and twice the rate of placebo) adverse reactions leading to discontinuation in the DAYTRANA group were application site reaction (2%), tics (1%), headache (1%), and irritability (1%).</paragraph>
                        <paragraph>In a 7-week double-blind, parallel-group, placebo-controlled study in adolescents with ADHD conducted in the outpatient setting, 5.5% (8/145) of patients treated with DAYTRANA discontinued due to adverse reactions compared with 2.8% (2/72) receiving placebo. The most commonly reported adverse reactions leading to discontinuation in the DAYTRANA group were application site reaction (2%) and decreased appetite/anorexia (1.4%).</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Commonly Observed Adverse Reactions in Double-Blind, Placebo-Controlled Trials</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin Irritation and Application Site Reactions</content>
                        </paragraph>
                        <paragraph>DAYTRANA is a dermal irritant. In addition to the most commonly reported adverse reactions presented in Table 2, the majority of subjects in those studies had minimal to definite skin erythema at the transdermal system application site. This erythema generally caused no or minimal discomfort and did not usually interfere with therapy or result in discontinuation from treatment. Erythema is not by itself a manifestation of contact sensitization. However, contact sensitization should be suspected if erythema is accompanied by evidence of a more intense local reaction (edema, papules, vesicles) that does not significantly improve within 48 hours or spreads beyond the transdermal system site [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#splSection19">5.10</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="italics">Most Commonly Reported Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Table 2 lists treatment-emergent adverse reactions reported in ≥ 1% DAYTRANA-treated children or adolescents with ADHD in two 7 week double-blind, parallel-group, placebo-controlled studies conducted in the outpatient setting. Overall, in these studies, 75.5% of children and 78.6% of adolescents experienced at least 1 adverse event.</paragraph>
                        <table ID="i87d7c0cf-a7a2-4245-84fc-dab8525dd220" width="800px">
                           <colgroup>
                              <col width="36%" align="left"/>
                              <col width="16%" align="center"/>
                              <col width="16%" align="center"/>
                              <col width="16%" align="center"/>
                              <col width="16%" align="center"/>
                           </colgroup>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="5" align="left">
                                    <paragraph styleCode="First Footnote">* Six subjects had affect lability, all judged as mild and described as increased emotionally sensitive, emotionality, emotional instability, emotional lability, and intermittent emotional</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="5" align="left">
                                    <content styleCode="bold">Table 2      Number (%) of Subjects with Commonly Reported Adverse Reactions (≥ 1% in the DAYTRANA Group) in 7-Week Placebo-controlled Studies in Either Children or Adolescents - Safety Population</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left"/>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" align="center">Adolescents</td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" align="center">Children</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left">System Organ Class <br/>   Preferred term</td>
                                 <td styleCode="Botrule Lrule" align="center">Placebo <br/>N = 72</td>
                                 <td styleCode="Botrule Rrule" align="center">DAYTRANA <br/>N = 145</td>
                                 <td styleCode="Botrule Lrule" align="center">Placebo <br/>N = 85</td>
                                 <td styleCode="Botrule Rrule" align="center">DAYTRANA <br/>N = 98</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule" align="left">Cardiac Disorders</td>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule" align="left">   Tachycardia</td>
                                 <td styleCode="Lrule" align="center">0 (0)</td>
                                 <td styleCode="Rrule" align="center">1 (0.7)</td>
                                 <td styleCode="Lrule" align="center">0 (0)</td>
                                 <td styleCode="Rrule" align="center">1 (1.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule" align="left">Gastrointestinal disorders</td>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule" align="left">   Abdominal pain</td>
                                 <td styleCode="Lrule" align="center">0 (0)</td>
                                 <td styleCode="Rrule" align="center">7 (4.8)</td>
                                 <td styleCode="Lrule" align="center">5 (5.9)</td>
                                 <td styleCode="Rrule" align="center">7 (7.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule" align="left">   Nausea</td>
                                 <td styleCode="Lrule" align="center">2 (2.8)</td>
                                 <td styleCode="Rrule" align="center">14 (9.7)</td>
                                 <td styleCode="Lrule" align="center">2 (2.4)</td>
                                 <td styleCode="Rrule" align="center">12 (12.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule" align="left">   Vomiting</td>
                                 <td styleCode="Botrule Lrule" align="center">1 (1.4)</td>
                                 <td styleCode="Botrule Rrule" align="center">5 (3.4)</td>
                                 <td styleCode="Botrule Lrule" align="center">4 (4.7)</td>
                                 <td styleCode="Botrule Rrule" align="center">10 (10.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Investigations</td>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left">   Weight decreased</td>
                                 <td styleCode="Botrule Lrule" align="center">1 (1.4)</td>
                                 <td styleCode="Botrule Rrule" align="center">8 (5.5)</td>
                                 <td styleCode="Botrule Lrule" align="center">0 (0)</td>
                                 <td styleCode="Botrule Rrule" align="center">9 (9.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Metabolism and nutrition disorders</td>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">   Anorexia</td>
                                 <td styleCode="Lrule" align="center">1 (1.4)</td>
                                 <td styleCode="Rrule" align="center">7 (4.8)</td>
                                 <td styleCode="Lrule" align="center">1 (1.2)</td>
                                 <td styleCode="Rrule" align="center">5 (5.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left">   Decreased appetite</td>
                                 <td styleCode="Botrule Lrule" align="center">1 (1.4)</td>
                                 <td styleCode="Botrule Rrule" align="center">37 (25.5)</td>
                                 <td styleCode="Botrule Lrule" align="center">4 (4.7)</td>
                                 <td styleCode="Botrule Rrule" align="center">25 (25.5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Nervous system disorders</td>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">   Dizziness</td>
                                 <td styleCode="Lrule" align="center">1 (1.4)</td>
                                 <td styleCode="Rrule" align="center">8 (5.5)</td>
                                 <td styleCode="Lrule" align="center">1 (1.2)</td>
                                 <td styleCode="Rrule" align="center">0 (0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left">   Headache</td>
                                 <td styleCode="Botrule Lrule" align="center">9 (12.5)</td>
                                 <td styleCode="Botrule Rrule" align="center">18 (12.4)</td>
                                 <td styleCode="Botrule Lrule" align="center">10 (11.8)</td>
                                 <td styleCode="Botrule Rrule" align="center">15 (15.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Psychiatric disorders</td>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Lrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">   Affect lability</td>
                                 <td styleCode="Lrule" align="center">1 (1.4)</td>
                                 <td styleCode="Rrule" align="center">0 (0)</td>
                                 <td styleCode="Lrule" align="center">0 (0)</td>
                                 <td styleCode="Rrule" align="center">6 (6.1)*</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">   Insomnia</td>
                                 <td styleCode="Lrule" align="center">2 (2.8)</td>
                                 <td styleCode="Rrule" align="center">9 (6.2)</td>
                                 <td styleCode="Lrule" align="center">4 (4.7)</td>
                                 <td styleCode="Rrule" align="center">13 (13.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">   Irritability</td>
                                 <td styleCode="Lrule" align="center">5 (6.9)</td>
                                 <td styleCode="Rrule" align="center">16 (11)</td>
                                 <td styleCode="Lrule" align="center">4 (4.7)</td>
                                 <td styleCode="Rrule" align="center">7 (7.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="left">   Tic</td>
                                 <td styleCode="Botrule Lrule" align="center">0 (0)</td>
                                 <td styleCode="Botrule Rrule" align="center">0 (0)</td>
                                 <td styleCode="Botrule Lrule" align="center">0 (0)</td>
                                 <td styleCode="Botrule Rrule" align="center">7 (7.1)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="Underline">Adverse Reactions in Clinical Studies with the Long-Term Use of DAYTRANA</content>
                        </paragraph>
                        <paragraph>In a long-term open-label study of up to 12 months duration in 326 children wearing DAYTRANA 9 hours daily, the most common (≥ 10%) adverse reactions were decreased appetite, headache, and weight decreased. A total of 30 subjects (9.2%) were withdrawn from the study due to adverse events and 22 additional subjects (6.7%) discontinued treatment as the result of an application site reaction. Other than application site reactions, affect lability (5 subjects, 1.5%) was the only additional adverse reaction leading to discontinuation reported with a frequency of greater than 1%.</paragraph>
                        <paragraph>In a long-term open-label study of up to 6 months duration in 162 adolescents wearing DAYTRANA 9 hours daily, the most common (≥ 10%) adverse reactions were decreased appetite and headache. A total of 9 subjects (5.5%) were withdrawn from the study due to adverse events and 3 additional subjects (1.9%) discontinued treatment as the result of an application site reaction. Other adverse reactions leading to discontinuation that occurred with a frequency of greater than 1% included affect lability and irritability (2 subjects each, 1.2%).</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection37">
                     <id root="8d07dd24-6538-499d-b6a2-61343fefc53d"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>In addition, the following adverse reactions have been identified during the post-approval use of DAYTRANA. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to DAYTRANA exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Cardiac Disorders: </content>palpitations.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Eye Disorders: </content>visual disturbances, blurred vision, increased intraocular pressure, mydriasis, and accommodation disorder.</paragraph>
                        <paragraph>
                           <content styleCode="bold">General Disorders and Administration Site Disorders</content>: fatigue, application site reactions such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, scab, swelling, ulcer, urticaria, vesicles, and warmth.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Immune System Disorders:</content> hypersensitivity reactions including generalized erythematous and urticarial rashes, allergic contact dermatitis, angioedema, and anaphylaxis.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Investigations:</content> blood pressure increased.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Nervous System Disorders</content>: convulsion, dyskinesia, lethargy, somnolence, serotonin syndrome in combination with serotonergic drugs, and extrapyramidal disorder, motor, and verbal tics.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Psychiatric Disorders</content>: depression, hallucination, nervousness, and libido changes.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>: alopecia.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Adverse Reactions with Oral Methylphenidate Products</content>
                        </paragraph>
                        <paragraph>Nervousness and insomnia are the most common adverse reactions reported with other methylphenidate products. In children, loss of appetite, abdominal pain, weight loss during prolonged therapy, insomnia, and tachycardia may occur more frequently; however, any of the other adverse reactions listed below may also occur.</paragraph>
                        <paragraph>Other reactions include:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Cardiac Disorders:</content> angina, arrhythmia, and pulse increased or decreased.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Immune System Disorders:</content> hypersensitivity reactions including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Metabolism and Nutrition Disorders:</content> anorexia and weight loss during prolonged therapy.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Nervous System Disorders:</content> drowsiness, rare reports of Tourette's syndrome and toxic psychosis.</paragraph>
                        <paragraph>Very rare reports of neuroleptic malignant syndrome (NMS) have been received, and, in most of these, patients were concurrently receiving therapies associated with NMS. In a single report, a ten-year-old boy who had been taking methylphenidate for approximately 18 months experienced an NMS-like event within 45 minutes of ingesting his first dose of venlafaxine. It is uncertain whether this case represented a drug-drug interaction, a response to either drug alone, or some other cause.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Vascular Disorders:</content> blood pressure increased or decreased and cerebral arteritis and/or occlusion.</paragraph>
                        <paragraph>Although a definite causal relationship has not been established, the following have been reported in patients taking methylphenidate:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Blood and Lymphatic System Disorders:</content> leukopenia and/or anemia.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Hepatobiliary Disorders:</content> abnormal liver function, ranging from transaminase elevation to severe hepatic injury.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Psychiatric Disorders:</content> transient depressed mood.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Skin and Subcutaneous Tissue Disorders:</content> scalp hair loss.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders:</content> rhabdomyolysis.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRDrugInteract">
               <id root="e23bfd63-e2a1-406c-aa0c-d8cefb78c480"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7	DRUG INTERACTIONS</title>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Antihypertensive Drugs: Monitor blood pressure. Adjust dosage of antihypertensive drug as needed. (<linkHtml href="#splSection25">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="splSection23">
                     <id root="68577a94-7e96-4649-9fba-d04099387bcc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Monoamine Oxidase Inhibitors (MAOI)</title>
                     <text>
                        <paragraph>Concomitant use of MAOIs and CNS stimulants, including DAYTRANA, can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure <content styleCode="Italics">[see Contraindications (<linkHtml href="#splSection12">4.2</linkHtml>)]</content>. Concomitant use of DAYTRANA with MAOIs or within 14 days after discontinuing MAOI treatment is contraindicated.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection25">
                     <id root="a37b8e0b-6fda-49b0-8653-1e5ef2ed63d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Antihypertensive Drugs</title>
                     <text>
                        <paragraph>DAYTRANA may decrease the effectiveness of drugs used to treat hypertension. Monitor blood pressure and adjust the dosage of the antihypertensive drug as needed <content styleCode="Italics">[see Warnings and Precautions (<linkHtml href="#splSection14">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection26">
                     <id root="d5194c68-3359-4e45-8950-7ec0d89d5d9d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Coumarin Anticoagulants, Antidepressants, and Selective Serotonin Reuptake Inhibitors</title>
                     <text>
                        <paragraph>Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (e.g., phenobarbital, phenytoin, primidone), and some tricyclic drugs (e.g., imipramine, clomipramine, desipramine) and selective serotonin reuptake inhibitors. Downward dose adjustments of these drugs may be required when given concomitantly with methylphenidate. It may be necessary to adjust the dosage and monitor plasma drug concentrations (or, in the case of coumarin, coagulation times), when initiating or discontinuing methylphenidate.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="L30cf7112-8e59-4cef-9a1c-f60e50807b03">
                     <id root="05939716-9336-4fea-b98f-14011b25d131"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Halogenated Anesthetics</title>
                     <text>
                        <paragraph>Concomitant use of halogenated anesthetics and methylphenidate may increase the risk of sudden blood pressure and heart rate increase during surgery. Avoid use of DAYTRANA in patients being treated with anesthetics on the day of surgery.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSection27">
                     <id root="77411b6f-af21-4726-b14b-c9f006df754f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Risperidone</title>
                     <text>
                        <paragraph>Combined use of methylphenidate with risperidone when there is a change in dosage, whether an increase or decrease, of either or both medications, may increase the risk of extrapyramidal symptoms (EPS). Monitor for signs of EPS.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRPopulations">
               <id root="69445903-af09-4093-8d55-de55ffc25477"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8	USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250523"/>
               <component>
                  <section ID="splSectionPLRPregnancy">
                     <id root="d8087bd9-6f82-4413-ab98-1d618aa07d8a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including DAYTRANA, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visit <linkHtml href="https://womensmentalhealth.org/adhd-medications/">https://womensmentalhealth.org/adhd-medications/</linkHtml>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Published studies and post-marketing reports on methylphenidate use during pregnancy are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the fetus associated with the use of CNS stimulants during pregnancy (<content styleCode="italics">see <linkHtml href="#CC">Clinical Considerations</linkHtml>)</content>.</paragraph>
                        <paragraph>No effects on morphological development were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis. However, spina bifida was observed in rabbits when given oral doses of 200 mg/kg/day. When methylphenidate was administered orally to rats throughout pregnancy and lactation, offspring growth and survival were decreased at maternally toxic doses <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinical recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                        <paragraph ID="CC">
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal adverse reactions</content>
                        </paragraph>
                        <paragraph>CNS stimulants, such as DAYTRANA, can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers.</paragraph>
                        <paragraph ID="data">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Animal reproduction toxicity studies with transdermal methylphenidate have not been performed. In embryo-fetal development studies conducted in rats and rabbits, methylphenidate was administered orally to pregnant animals during the period of organogenesis, at doses up to 100 and 200 mg/kg/day, respectively. No evidence of morphological development effects was found either of the species; however, increased incidences of fetal skeletal variations were observed in rats at 60 mg/kg or greater and an increase in fetal visceral variations was seen in rabbits at the highest dose. In a previous study, methylphenidate was shown to have malformations (increased incidence of fetal spina bifida) in rabbits when given oral doses of 200 mg/kg/day. When methylphenidate was administered orally to rats throughout pregnancy and lactation at doses of up to 60 mg/kg/day, offspring growth and survival were decreased at maternally toxic doses.</paragraph>
                        <paragraph>In a study in which oral methylphenidate was given to rats throughout pregnancy and lactation at doses up to 60 mg/kg/day, offspring weights and survival were decreased at 40 mg/kg/day and above; these doses caused some maternal toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSectionPLRLabor">
                     <id root="739e7c63-5cd3-4f4f-a0b8-f17ac63febb5"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. Long-term neurodevelopmental effects on infants from stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DAYTRANA and any potential adverse effects on the breastfed infant from DAYTRANA or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSectionPLRPediatric">
                     <id root="19466de7-d1d8-4161-9db6-f15f4480c755"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of DAYTRANA in pediatric patients less than 6 years have not been established. Long-term effects of methylphenidate in children have not been well established.</paragraph>
                        <paragraph>The safety and effectiveness of DAYTRANA for the treatment of ADHD have been established in pediatric patients 6 to 17 years.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Long Term Suppression of Growth</content>
                        </paragraph>
                        <paragraph>Growth should be monitored during treatment with stimulants, including DAYTRANA. Children who are not growing or gaining weight as expected may need to have their treatment interrupted <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection18">5.8</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Juvenile Animal Toxicity Data</content>
                        </paragraph>
                        <paragraph>Rats treated with methylphenidate early in the postnatal period through sexual maturation demonstrated a decrease in spontaneous locomotor activity in adulthood. A deficit in acquisition of a specific learning task was observed in females only.</paragraph>
                        <paragraph>Studies with transdermal methylphenidate have not been performed in juvenile animals. In a study conducted in young rats, methylphenidate was administered orally at doses of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (Postnatal Day 7) and continuing through sexual maturity (Postnatal Week 10). When these animals were tested as adults (Postnatal Weeks 13-14), decreased spontaneous locomotor activity was observed in males and females previously treated with 50 mg/kg/day or greater, and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dose. The no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day. The clinical significance of the long-term behavioral effects observed in rats is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSectionPLRGeriatric">
                     <id root="6390ed37-b8ad-4c87-a15d-596e314b003e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>DAYTRANA has not been studied in patients greater than 65 years of age.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRDrugAbuse">
               <id root="5004ae12-36cb-4d8b-910f-2593756b0ec3"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9	DRUG ABUSE AND DEPENDENCE</title>
               <text/>
               <effectiveTime value="20250523"/>
               <component>
                  <section ID="splSectionPLRControlled">
                     <id root="d9bf7edd-7426-487c-b583-c7873b15e216"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>DAYTRANA contains methylphenidate, a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSectionPLRAbuse">
                     <id root="22d2ffbb-22e1-496b-b2ad-788dc1c66fee"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>DAYTRANA has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection13">5.1</linkHtml>)]</content>. DAYTRANA can be diverted for non-medical use into illicit channels or distribution.</paragraph>
                        <paragraph>Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.</paragraph>
                        <paragraph>Misuse and abuse of methylphenidate may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#splSectionPLROverdose">10</linkHtml>)]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSectionPLRDependence">
                     <id root="870a0d64-1d9f-4008-be2d-cdf972b5c2b3"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Physical Dependence</content>
                        </paragraph>
                        <paragraph>DAYTRANA may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.</paragraph>
                        <paragraph>Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including DAYTRANA include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Tolerance</content>
                        </paragraph>
                        <paragraph>DAYTRANA may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLROverdose">
               <id root="c026053d-250b-42d1-8026-fd77cc9089a1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Effects of Overdose</content>
                  </paragraph>
                  <paragraph>Overdose of CNS stimulants is characterized by the following sympathomimetic effects:</paragraph>
                  <list listType="unordered">
                     <item>Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.</item>
                     <item>CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.</item>
                     <item>Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Overdose Management</content>
                  </paragraph>
                  <paragraph>Consider the possibility of multiple drug ingestion. Because methylphenidate has a large volume of distribution and is rapidly metabolized, dialysis is not useful. Remove all transdermal systems immediately and cleanse the area(s) to remove any remaining adhesive. The continuing absorption of methylphenidate from the skin, even after removal of the transdermal system, should be considered when treating patients with overdose.</paragraph>
                  <paragraph>Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250523"/>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRDescription">
               <id root="11354a2a-966c-4784-bcbe-46aee206f10c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>
                     <content>DAYTRANA is an adhesive-based matrix transdermal system containing methylphenidate that is applied to intact skin. The chemical name for methylphenidate is α-phenyl-2-piperidineacetic acid methyl ester. It is a white to off-white powder and is soluble in alcohol, ethyl acetate, and ether. Methylphenidate is practically insoluble in water and petrol ether. Its molecular weight is 233.31. Its empirical formula is C</content>
                     <sub>14</sub>
                     <content>H</content>
                     <sub>19</sub>
                     <content>NO</content>
                     <sub>2</sub>
                     <content>. The structural formula of methylphenidate is:</content>
                  </paragraph>
                  <paragraph>
                     <content>
                        <renderMultiMedia referencedObject="L7b27607a-9fbd-44ad-b048-0ae07bcbe314"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Transdermal System Components</content>
                  </paragraph>
                  <paragraph>DAYTRANA contains methylphenidate in a multipolymeric adhesive. The methylphenidate is dispersed in acrylic adhesive that is dispersed in a silicone adhesive. The composition per unit area of all dosage strengths is identical, and the total dose delivered is dependent on the transdermal system size and wear time.</paragraph>
                  <paragraph>DAYTRANA consists of three layers, as seen in the figure below (cross-section of the transdermal system).</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L3281c090-a09a-4287-a7fb-f11eabd51758"/>
                  </paragraph>
                  <paragraph>
                     <content>Proceeding from the outer surface toward the surface adhering to the skin, the layers are (1) a polyester/ethylene vinyl acetate laminate film backing, (2) a proprietary adhesive formulation incorporating Noven Pharmaceuticals, Inc.'s DOT Matrix™ transdermal technology consisting of an acrylic adhesive, a silicone adhesive, and methylphenidate, and (3) a fluoropolymer-coated polyester protective liner, which is attached to the adhesive surface and must be removed before the transdermal system can be used.</content>
                  </paragraph>
                  <paragraph>The active component of the transdermal system is methylphenidate. The remaining components are pharmacologically inactive.</paragraph>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <observationMedia ID="L7b27607a-9fbd-44ad-b048-0ae07bcbe314">
                     <text>daytrana-structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L3281c090-a09a-4287-a7fb-f11eabd51758">
                     <text>daytrana-figure-section</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRClinicalPharm">
               <id root="c2aa5966-0a4c-4aac-a274-c1998c838e68"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20250527"/>
               <component>
                  <section ID="splSectionPLRMechAction">
                     <id root="9666a743-ddde-4808-a679-935fee464774"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Methylphenidate is a CNS stimulant. Its mode of therapeutic action in ADHD is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section ID="splSectionPLRPharmacodynamics">
                     <id root="dadd35bb-16f2-43e4-ad7e-83d789f299f4"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Methylphenidate is a racemic mixture comprised of the <content styleCode="italics">d-</content>and <content styleCode="italics">l-</content>enantiomers. The <content styleCode="italics">d-</content>enantiomer is more pharmacologically active than the <content styleCode="italics">l-</content>enantiomer. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="splSectionPLRPharmacokinetics">
                     <id root="d0b50dfb-30ce-4b7c-ab30-d45a23fa4f5d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph/>
                        <paragraph>The pharmacokinetics of DAYTRANA when applied to the hip for 9 hours have been studied in ADHD patients 6 to 17 years old.</paragraph>
                        <paragraph ID="S1203-1">Absorption</paragraph>
                        <paragraph>The amount of methylphenidate absorbed systemically is a function of both wear time and transdermal system size. In patients with ADHD, peak plasma levels of methylphenidate are reached at about 10 hours after single application and 8 hours after repeat transdermal system applications (12.5cm<sup>2</sup> to 37.5cm<sup>2</sup>) when worn up to 9 hours.</paragraph>
                        <paragraph>On single dosing of children or adolescents with DAYTRANA, there was a delay of, on average, 2 hours before <content styleCode="italics">d</content>-methylphenidate was detectable in the circulation. On repeat dosing, low concentrations (1.2-3.0 ng/mL in children and 0.5-1.7ng/mL in adolescents, on average across the dose range) were observed earlier in the profile, due to carry-over effect. Following the application of DAYTRANA once daily with a 9-hour wear time, the mean pharmacokinetic parameters of <content styleCode="italics">d</content>-methylphenidate in children and adolescents with ADHD after 4 weeks of therapy are summarized in Table 3.</paragraph>
                        <table ID="id946807d-f65f-4260-8ef3-8cd7e931fb48" width="800">
                           <colgroup>
                              <col width="20%" align="center"/>
                              <col width="20%" align="center"/>
                              <col width="20%" align="center"/>
                              <col width="20%" align="center"/>
                              <col width="20%" align="center"/>
                           </colgroup>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="5" align="left">
                                    <paragraph styleCode="First Footnote">
                                       <sup>1</sup> Dose maintained fixed for 28 days;</paragraph>
                                    <paragraph styleCode="Footnote">
                                       <sup>2</sup> Dose escalated at 7 day intervals from 12.5 cm<sup>2</sup> through 18.75 cm<sup>2</sup> and 25 cm<sup>2</sup> to 37.5 cm<sup>2</sup>;</paragraph>
                                    <paragraph styleCode="Footnote">
                                       <sup>3</sup> Dose escalated at 7 day intervals from 18 mg through 27 mg and 36 mg to 54 mg;</paragraph>
                                    <paragraph styleCode="Footnote">
                                       <sup>4</sup> Median (minimum - maximum); t <sub>lag</sub> = Last Sampling Time Prior to Time of First Quantifiable Plasma Concentration</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule" colspan="5" align="center">
                                    <content styleCode="bold">Table 3 <br/>Mean Plasma d-Methylphenidate Pharmacokinetic Parameters After Repeated 9-Hour Applications of DAYTRANA or Oral ER-MPH for up to 28 days to Pediatric ADHD Patients (Aged 6 - 17 years) </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" colspan="5" align="left">
                                    <content styleCode="italics">Children</content>
                                 </td>
                              </tr>
                              <tr valign="top">
                                 <td styleCode="Botrule" align="center">Parameter</td>
                                 <td styleCode="Botrule" align="center">DAYTRANA <sup>1</sup>
                                    <br/>12.5cm <sup>2</sup>
                                    <br/>(N=12)</td>
                                 <td styleCode="Botrule" align="center">DAYTRANA <sup>2</sup>
                                    <br/>37.5cm <sup>2</sup>
                                    <br/>(N=10)</td>
                                 <td styleCode="Botrule" align="center">Oral ER-MPH <sup>3</sup>
                                    <br/>18mg</td>
                                 <td styleCode="Botrule" align="center">Oral ER-MPH <sup>3</sup>
                                    <br/>54mg</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrul" align="center">C <sub>ssmax</sub>
                                    <br/>(ng/mL)</td>
                                 <td align="center">15.7 ± 9.39</td>
                                 <td align="center">42.9 ± 22.4</td>
                                 <td align="center">8.37 ± 4.14</td>
                                 <td align="center">26.1 ± 11.2</td>
                              </tr>
                              <tr>
                                 <td align="center">C <sub>ssmin</sub>
                                    <br/>(ng/mL)</td>
                                 <td align="center">1.04 ± 1.17</td>
                                 <td align="center">1.96 ± 1.73</td>
                                 <td align="center">0.708 ± 1.08</td>
                                 <td align="center">1.19 ± 1.54</td>
                              </tr>
                              <tr>
                                 <td align="center">AUC <sub>ss </sub>
                                    <br/>(ng·hr/mL)</td>
                                 <td align="center">163 ± 101</td>
                                 <td align="center">447 ± 230</td>
                                 <td align="center">97.7 ± 67.0</td>
                                 <td align="center">317 ± 160</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" align="center">t <sub>lag</sub>
                                    <br/>(h) <sup>4</sup>
                                 </td>
                                 <td styleCode="Botrule" align="center">0 (0 - 2.0)</td>
                                 <td styleCode="Botrule" align="center">0 (0 - 1.0)</td>
                                 <td styleCode="Botrule" align="center">0</td>
                                 <td styleCode="Botrule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" colspan="5" align="left">
                                    <content styleCode="italics">Adolescents</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">C <sub>ssmax </sub>
                                    <br/>(ng/mL)</td>
                                 <td align="center">8.32 ± 4.60</td>
                                 <td align="center">16.5 ± 6.94</td>
                                 <td align="center">5.23 ± 1.72</td>
                                 <td align="center">18.0 ± 6.97</td>
                              </tr>
                              <tr>
                                 <td align="center">C <sub>ssmin</sub>
                                    <br/>(ng/mL)</td>
                                 <td align="center">0.544 ± 0.383</td>
                                 <td align="center">1.02 ± 0.629</td>
                                 <td align="center">0.360 ± 0.478</td>
                                 <td align="center">1.50 ± 0.937</td>
                              </tr>
                              <tr>
                                 <td align="center">AUC <sub>ss </sub>
                                    <br/>(ng·hr/mL)</td>
                                 <td align="center">85.7 ± 50.0</td>
                                 <td align="center">167 ± 66.0</td>
                                 <td align="center">59.7 ± 19.1</td>
                                 <td align="center">216 ± 80.8</td>
                              </tr>
                              <tr>
                                 <td align="center">t <sub>lag</sub>
                                    <br/>(h) <sup>4</sup>
                                 </td>
                                 <td align="center">0 (0 - 2.0)</td>
                                 <td align="center">0 (0 - 2.0)</td>
                                 <td align="center">0</td>
                                 <td align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Following administration of DAYTRANA 12.5cm<sup>2</sup> to pediatric and adolescent ADHD patients daily for 7 days, there were 13% and 14% increases, respectively, in steady state area under the plasma concentration-time curve (AUC <sub>ss</sub>) relative to that anticipated on the basis of single dose pharmacokinetics (AUC0 <sub>-∞</sub>); after 28 days administration, these increments increased to 64% and 76%, respectively. C <sub>max</sub> increased by nearly 69% and 100% within 4 weeks of daily administration of the starting dose in children and adolescents, respectively.</paragraph>
                        <paragraph>The observed exposures with DAYTRANA could not be explained by drug accumulation predicted from observed single dose pharmacokinetics and there was no evidence that clearance or rate of elimination changed between single and repeat dosing. Neither were they explainable by differences in dosing patterns between treatments, age, race, or gender. This suggests that transdermal absorption of methylphenidate may increase with repeat dosing with DAYTRANA; on average, steady-state is likely to have been achieved by approximately 14 days of dosing.</paragraph>
                        <paragraph>In the single- and multiple dose study described above, exposure to <content styleCode="italics">l-</content>methylphenidate was 46% of the exposure to <content styleCode="italics">d-</content>methylphenidate in children and 40% in adolescents. <content styleCode="italics">l</content>-methylphenidate is less pharmacologically active than <content styleCode="italics">d</content>-methylphenidate <content styleCode="italics">[see Pharmacodynamics (<linkHtml href="#splSectionPLRPharmacodynamics">12.2</linkHtml>)] </content>.</paragraph>
                        <paragraph>In a phase 2 PK/PD study in children aged 6-12 years, 2/3 of patients had 2-hour <content styleCode="italics">d-</content>MPH concentrations &lt; 5 ng/mL on chronic dosing, and at 3 hours 40% of patients had <content styleCode="italics">d-</content>MPH concentrations &lt; 5 ng/mL <content styleCode="italics">[see Clinical Studies (<linkHtml href="#splSectionPLRClinicalStudies">14</linkHtml>)] </content>.</paragraph>
                        <paragraph>When DAYTRANA is applied to inflamed skin both the rate and extent of absorption are increased as compared with intact skin. When applied to inflamed skin, lag time is no greater than 1 hour, T <sub>max</sub> is 4 hours, and both C <sub>max</sub> and AUC are approximately 3-fold higher.</paragraph>
                        <paragraph>When heat is applied to DAYTRANA after application, both the rate and the extent of absorption are significantly increased. Median T <sub>lag</sub> occurs 1 hour earlier, T <sub>max</sub> occurs 0.5 hours earlier, and median C <sub>max</sub> and AUC are 2-fold and 2.5-fold higher, respectively.</paragraph>
                        <paragraph>Application sites other than the hip can have different absorption characteristics and have not been adequately studied in safety or efficacy studies.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Dose Proportionality</content>
                        </paragraph>
                        <paragraph>Following a single 9-hour application of DAYTRANA doses of 10 mg / 9 hours to 30 mg / 9 hours transdermal systems to 34 children with ADHD, C <sub>max</sub> and AUC <sub>0-t</sub> of <content styleCode="italics">d</content>-methylphenidate were proportional to the transdermal system dose. Mean plasma concentration-time plots are shown in Figure 1. C <sub>max</sub> of <content styleCode="italics">l</content>-methylphenidate was also proportional to the transdermal system dose. AUC <sub>0-t</sub> of <content styleCode="italics">l</content>-methylphenidate was only slightly greater than proportional to transdermal system dose.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="Lae3ee97b-0916-4631-8e59-283cead65e4e"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Distribution</content>
                        </paragraph>
                        <paragraph>Upon removal of DAYTRANA, methylphenidate plasma concentrations in children with ADHD decline in a biexponential manner. This may be due to continued distribution of MPH from the skin after transdermal system removal.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Metabolism and Excretion</content>
                        </paragraph>
                        <paragraph>Methylphenidate is metabolized primarily by de-esterification to alpha-phenyl-piperidine acetic acid (ritalinic acid), which has little or no pharmacologic activity.</paragraph>
                        <paragraph>Transdermal administration of methylphenidate exhibits much less first pass effect than oral administration. Consequently, a much lower dose of DAYTRANA on a mg/kg basis compared to oral dosages may still produce higher exposures of <content styleCode="italics">d-</content>MPH with transdermal administration compared to oral administration. In addition, very little, if any, <content styleCode="italics">l-</content>methylphenidate is systemically available after oral administration due to first pass metabolism, whereas after transdermal administration of racemic methylphenidate exposure to <content styleCode="italics">l-</content>methylphenidate is nearly as high as to <content styleCode="italics">d-</content>methylphenidate.</paragraph>
                        <paragraph>The mean elimination t <sub>1/2</sub> from plasma of <content styleCode="italics">d-</content>methylphenidate after removal of DAYTRANA in children aged 6 to 12 years and adolescents aged 13-17 years was approximately 4 to 5 hours. The t <sub>1/2 </sub>of <content styleCode="italics">l-</content>methylphenidate was shorter than for <content styleCode="italics">d-</content>methylphenidate and ranged from 1.4 to 2.9 hours, on average.</paragraph>
                        <paragraph>The C <sub>max</sub> and AUC of <content styleCode="italics">d</content>-methylphenidate were approximately 50% lower in adolescents, compared to children, following either a 1-day or 7-day administration of DAYTRANA (10mg/9hr). Multiple-dose administration of DAYTRANA did not result in significant accumulation of methylphenidate; following 7 days of DAYTRANA administration (10mg/9hr) in children and adolescents, the accumulation index of methylphenidate was 1.1, based on the mean steady state area under the plasma concentration-time curve (AUC <sub>ss</sub>) relative to that anticipated on the basis of single dose pharmacokinetics (AUC <sub>0-∞</sub>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Food Effects</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics or the pharmacodynamic food effect performance after application of DAYTRANA has not been studied, but because of the transdermal route of administration, no food effect is expected.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Special Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gender</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of methylphenidate after single and repeated doses of DAYTRANA were similar between boys and girls with ADHD, after allowance for differences in body weight.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Race</content>
                        </paragraph>
                        <paragraph>The influence of race on the pharmacokinetics of methylphenidate after administration of DAYTRANA has not been defined.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Age</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of methylphenidate after administration of DAYTRANA have not been studied in children less than 6 years of age.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>There is no experience with the use of DAYTRANA in patients with renal insufficiency.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>There is no experience with the use of DAYTRANA in patients with hepatic insufficiency.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                     <component>
                        <observationMedia ID="Lae3ee97b-0916-4631-8e59-283cead65e4e">
                           <text>daytrana-03</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="daytrana-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRNonClinical">
               <id root="5a2fff63-0544-4e0f-a924-5f2acad89d62"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20250523"/>
               <component>
                  <section ID="splSectionPLRPrecautionsCarcinogen">
                     <id root="754e4fdb-4b3a-4e43-8a38-7d4fd4f987fb"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis/Mutagenesis and Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Carcinogenicity studies of transdermal methylphenidate have not been performed. In a lifetime carcinogenicity study of oral methylphenidate carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas, at a daily dose of approximately 60 mg/kg/day. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors and the significance of these results to humans is unknown.</paragraph>
                        <paragraph>Orally administered methylphenidate did not cause any increases in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dose used was approximately 45 mg/kg/day.</paragraph>
                        <paragraph>In a 24-week oral carcinogenicity study in the transgenic mouse strain p53<sup>+/-</sup>, which is sensitive to genotoxic carcinogens, there was no evidence of carcinogenicity. In this study, male and female mice were fed diets containing the same concentration of methylphenidate as in the lifetime carcinogenicity study; the high-dose groups were exposed to 60 to 74 mg/kg/day of methylphenidate.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Methylphenidate was not mutagenic in the <content styleCode="italics">in vitro</content> Ames reverse mutation assay or in the <content styleCode="italics">in vitro</content> mouse lymphoma cell forward mutation assay. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an <content styleCode="italics">in vitro</content> assay in cultured Chinese hamster ovary cells. Methylphenidate was negative <content styleCode="italics">in vivo</content> in males and females in the mouse bone marrow micronucleus assay.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Methylphenidate did not impair fertility in male or female mice that were fed diets containing the drug in an 18-week continuous breeding study. The study was conducted at doses up to 160 mg/kg/day.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRClinicalStudies">
               <id root="bb4455e3-593f-4fb8-a093-f6e7aac1d124"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>DAYTRANA was demonstrated to be effective in the treatment of ADHD in two (2) randomized double-blind, placebo-controlled studies in children aged 6 to 12 years and one (1) randomized, double-blind, placebo-controlled study in adolescents aged 13 to 17 years who met Diagnostic and Statistical Manual (DSM-IV-TR<sup>®</sup>) criteria for ADHD. DAYTRANA wear time was 9 hours in all three (3) studies.</paragraph>
                  <paragraph>In Study 1, conducted in a classroom setting, symptoms of ADHD were evaluated by school teachers and observers using the Deportment Subscale from the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) rating scale which assesses behavior symptoms in the classroom setting. DAYTRANA was applied for 9 hours before removal. There was a 5-week open-label DAYTRANA dose optimization phase using dosages of 10, 15, 20, and 30 mg / 9 hours, followed by a 2-week randomized, double-blind, placebo-controlled crossover treatment phase using the optimal transdermal system dose for each patient or placebo. The mean differences between DAYTRANA and placebo in change from baseline in SKAMP Deportment Scores were statistically significant in favor of DAYTRANA beginning at 2 hours and remained statistically significant at all subsequent measured time points through 12 hours after application of DAYTRANA.</paragraph>
                  <paragraph>In Study 2, conducted in the outpatient setting, DAYTRANA or placebo was blindly administered in a flexible-dose design using doses of 10, 15, 20, and 30 mg / 9 hours to achieve an optimal regimen over 5 weeks, followed by a 2-week maintenance period using the optimal transdermal system dose for each patient. Symptoms of ADHD were evaluated by the ADHD-Rating Scale (RS)-IV. DAYTRANA was statistically significantly superior to placebo as measured by the mean change from baseline for the ADHD-RS-IV total score. Although this study was not designed specifically to evaluate dose response, in general there did not appear to be any additional effectiveness accomplished by increasing the transdermal system dose from 20 mg / 9 hours to 30 mg / 9 hours.</paragraph>
                  <paragraph>In Study 3, conducted in the outpatient setting, DAYTRANA or placebo was blindly administered in a flexible-dose design using doses of 10, 15, 20, and 30 mg / 9 hours during a 5-week dose-optimization phase, followed by a 2-week maintenance period using the optimal transdermal system dose for each patient. Symptoms of ADHD were evaluated using the ADHD-Rating Scale (RS)-IV. DAYTRANA was statistically significantly superior to placebo as measured by the mean change from baseline in the ADHD-RS-IV total score.</paragraph>
               </text>
               <effectiveTime value="20250523"/>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRHowSupplied">
               <id root="c513e8c8-ad0b-479f-8747-1f0aed2aca17"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
              DAYTRANA is supplied in a sealed tray containing 30 individually pouched transdermal systems. See the chart below for information regarding available strengths.
            </paragraph>
                  <table ID="i9c09cba4-e830-477f-8910-91248a9757c6" width="800px">
                     <colgroup>
                        <col width="20%" align="center"/>
                        <col width="14%" align="center"/>
                        <col width="14%" align="center"/>
                        <col width="22%" align="center"/>
                        <col width="12%" align="center"/>
                        <col width="18%" align="center"/>
                     </colgroup>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td colspan="6" align="left">
                              <paragraph styleCode="First Footnote">*Nominal <content styleCode="italics">in vivo</content> delivery rate per hour in children and adolescents when applied to the hip, based on a 9-hour wear period.</paragraph>
                              <paragraph styleCode="Footnote">**Methylphenidate content in each transdermal system.</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr valign="top">
                           <td styleCode="Botrule" align="center">
                              <content styleCode="bold">Nominal Dose <br/>Delivered (mg) <br/>Over 9 Hours </content>
                           </td>
                           <td styleCode="Botrule" align="center">
                              <content styleCode="bold">Dosage <br/>Rate* <br/>(mg/hr) </content>
                           </td>
                           <td styleCode="Botrule" align="center">
                              <content styleCode="bold">Transdermal System<br/>Size (cm <sup>2</sup>) </content>
                           </td>
                           <td styleCode="Botrule" align="center">
                              <content styleCode="bold">Methylphenidate <br/>Content per <br/>Transdermal System** (mg) </content>
                           </td>
                           <td styleCode="Botrule" align="center">
                              <content styleCode="bold">Transdermal Systems<br/>Per <br/>Carton </content>
                           </td>
                           <td styleCode="Botrule" align="center">
                              <content styleCode="bold">NDC Number</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="center">10</td>
                           <td styleCode="Botrule" align="center">1.1</td>
                           <td styleCode="Botrule" align="center">12.5</td>
                           <td styleCode="Botrule" align="center">27.5</td>
                           <td styleCode="Botrule" align="center">30</td>
                           <td styleCode="Botrule" align="center">68968-5552-3</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="center">15</td>
                           <td styleCode="Botrule" align="center">1.6</td>
                           <td styleCode="Botrule" align="center">18.75</td>
                           <td styleCode="Botrule" align="center">41.3</td>
                           <td styleCode="Botrule" align="center">30</td>
                           <td styleCode="Botrule" align="center">68968-5553-3</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="center">20</td>
                           <td styleCode="Botrule" align="center">2.2</td>
                           <td styleCode="Botrule" align="center">25</td>
                           <td styleCode="Botrule" align="center">55</td>
                           <td styleCode="Botrule" align="center">30</td>
                           <td styleCode="Botrule" align="center">68968-5554-3</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="center">30</td>
                           <td styleCode="Botrule" align="center">3.3</td>
                           <td styleCode="Botrule" align="center">37.5</td>
                           <td styleCode="Botrule" align="center">82.5</td>
                           <td styleCode="Botrule" align="center">30</td>
                           <td styleCode="Botrule" align="center">68968-5555-3</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store at 25° C (77° F); excursions permitted to 15-30° C (59-86° F) [see USP Controlled Room Temperature]. Do not store transdermal systems unpouched. Do not store transdermal systems in refrigerators or freezers.</paragraph>
                  <paragraph>
              Once the sealed tray is opened, use contents within 2 months. Apply the transdermal system immediately upon removal from the individual protective pouch. For transdermal use only.
            </paragraph>
                  <paragraph>See the <content styleCode="italics">Patient Counseling Information (<linkHtml href="#splSectionPLRPatientInfo">17</linkHtml>)</content> for specific disposal instructions for unused or expired DAYTRANA.</paragraph>
               </text>
               <effectiveTime value="20250602"/>
            </section>
         </component>
         <component>
            <section ID="splSectionPLRPatientInfo">
               <id root="a5393947-b223-44fb-b0f4-5ab83ab90ef7"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Abuse, Misuse, and Addiction</content>
                  </paragraph>
                  <paragraph>Educate patients and their families about the risks of abuse, misuse, and addiction of DAYTRANA, which can lead to overdose and death, and proper disposal of any unused drug <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection13">5.1</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#splSectionPLRAbuse">9.2</linkHtml>), Overdosage (<linkHtml href="#splSectionPLROverdose">10</linkHtml>)]</content>. Advise patients to store DAYTRANA in a safe place, preferably locked, and instruct patients to not give DAYTRANA to anyone else.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Special Disposal Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients that there are special disposal instructions for unused or expired DAYTRANA <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection13">5.1</linkHtml>)]</content>. Instruct patients to find a take back location to dispose of unused or expired DAYTRANA. If a take back program is unavailable, instruct them to:</paragraph>
                  <list listType="ordered">
                     <item>Remove DAYTRANA from its pouch, separate it from its liner, fold it in half with the adhesive sides touching each other, and immediately flush it down the toilet, and</item>
                     <item>Place the pouch and liner in a container, close the container, and throw out the container in the trash (advise patients not to flush the pouch and liner down the toilet).</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Risks to Patients with Serious Cardiac Disease</content>
                  </paragraph>
                  <paragraph>Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with DAYTRANA use. Instruct patients to contact a healthcare provider immediately if they develop symptoms, such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection14">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Priapism</content>
                  </paragraph>
                  <paragraph>Advise patients, caregivers, and family members of the possibility of painful or prolonged penile erections (priapism). Instruct the patient to seek immediate medical attention in the event of priapism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#b8b-0800200c9a66-5-5">5.6</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Circulation problems in fingers and toes</content> [Peripheral vasculopathy, including Raynaud’s phenomenon] <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#AS560">5.7</linkHtml>)]</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Instruct patients beginning treatment with DAYTRANA about the risk of peripheral vasculopathy, including Raynaud’s Phenomenon, and in associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.</item>
                     <item>Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.</item>
                     <item>Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while using DAYTRANA.</item>
                     <item>Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Long-Term Suppression of Growth in Pediatric Patients</content>
                  </paragraph>
                  <paragraph>Advise patients that DAYTRANA may cause slowing of growth including weight loss <content styleCode="italics">[see Warnings and (<linkHtml href="#splSection18">5.8</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Chemical Leukoderma</content>
                  </paragraph>
                  <paragraph>Advise patients of the possibility of a persistent loss of skin pigmentation at, around and distant from the application site. Advise patients to immediately inform their healthcare provider if changes in skin pigmentation occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#splSection17">5.9</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Increased Intraocular Pressure (IOP) and Glaucoma</content>
                  </paragraph>
                  <paragraph>Advise patients that IOP and glaucoma may occur during treatment with DAYTRANA <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Lc0619838-7850-4b18-b7d3-d7a767cf7b44">5.14</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Motor and Verbal Tics, and Worsening of Tourette’s Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients that motor and verbal tics and worsening of Tourette’s Syndrome may occur during treatment with DAYTRANA. Instruct patients to notify their healthcare provider if emergence of new tics or worsening of tics or Tourette’s syndrome occurs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#L03491982-bb93-48f5-bdbf-c85f1acf757e">5.15</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Important Preparation and Administration Instructions<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#splSection5">2.3</linkHtml>)]</content>
                     </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>﻿Parents and patients should be informed to apply DAYTRANA to a clean, dry site on the hip, which is not oily, damaged, or irritated. The site of application must be alternated daily. DAYTRANA should not be applied to the waistline, or where tight clothing may rub it.﻿</item>
                     <item>If patients or caregivers experience difficulty separating the transdermal system from the release liner or observe tearing and/or other damage to the transdermal system during removal from the liner, the transdermal system should be discarded according to the directions provided in this label, and a new transdermal system should be applied <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#splSection5">2.3</linkHtml>)]</content>. Patients or caregivers should inspect the release liner to ensure that no adhesive containing medication has transferred to the liner. If adhesive transfer has occurred, the transdermal system should be discarded.</item>
                     <item>DAYTRANA should be applied 2 hours before the desired effect. DAYTRANA should be removed approximately 9 hours after it is applied, although the effects from the transdermal system will last for several more hours. DAYTRANA may be removed earlier than 9 hours if a shorter duration of effect is desired or late day side effects appear.</item>
                     <item>The parent or caregiver should be encouraged to use the administration chart included with each carton of DAYTRANA to monitor application and removal time, and method of disposal. The Medication Guide included at the end of this insert also includes a timetable to calculate when to remove DAYTRANA, based on the 9 hour application time.</item>
                     <item>Patients or caregivers should avoid touching the adhesive side of the transdermal system during application, in order to avoid absorption of methylphenidate. If they do touch the adhesive side of the transdermal system, they should immediately wash their hands after application.</item>
                     <item>In the event that a DAYTRANA does not fully adhere to the skin upon application, or is partially or fully detached during wear time, the transdermal system should be discarded according to the directions provided in this label, and a new transdermal system should be applied <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#splSection5">2.3</linkHtml>)]</content>. If a transdermal system is replaced, the total recommended wear time for that day should remain 9 hours, regardless of the number of transdermal systems used.</item>
                     <item>DAYTRANA should not be applied or re-applied with dressings, tape, or other common adhesives.</item>
                     <item>Exposure to water during bathing, swimming, or showering can affect transdermal system adherence.</item>
                     <item>Do not cut transdermal systems. Only intact transdermal systems should be applied.</item>
                     <item>If there is an unacceptable duration of appetite loss or insomnia in the evening, taking the transdermal system off earlier may be attempted before decreasing the transdermal system dose.</item>
                     <item>Skin redness or itching is common with DAYTRANA and small bumps on the skin may also occur in some patients. If any swelling or blistering occurs the DAYTRANA should not be worn and the patient should be seen by the prescriber. Patients or caregivers should not apply hydrocortisone or other solutions, creams, ointments, or emollients immediately prior to DAYTRANA application, since the effect on transdermal system adhesion and methylphenidate absorption has not been established. The potential adverse effects of topical corticosteroid use during treatment with DAYTRANA are unknown.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Recommended Storage Instructions</content>
                  </paragraph>
                  <paragraph>Transdermal systems should be stored at 25 degrees Celsius (77 degrees Fahrenheit) with excursions permitted that do not exceed 15 to 30 degrees Celsius (59 to 86 degrees Fahrenheit) <content styleCode="italics">[see How Supplied/Storage and Handling (<linkHtml href="#splSectionPLRHowSupplied">16</linkHtml>)]</content>. Patients or caregivers should be advised not to store DAYTRANA in the refrigerator or freezer.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy Registry</content>
                  </paragraph>
                  <paragraph>Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including DAYTRANA, during pregnancy [<content styleCode="italics">see Use in Specific Populations (<linkHtml href="#splSectionPLRPregnancy">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>Manufactured for: Noven Therapeutics, LLC, Miami, FL 33186.</paragraph>
                  <paragraph>By: Noven Pharmaceuticals, Inc., Miami, FL 33186.</paragraph>
                  <paragraph>For more information, call 1-800-455-8070 or visit <content styleCode="underline">www.daytrana.com</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">DOT Matrix™ is a trademark of Noven Pharmaceuticals, Inc. <br/>DAYTRANA<sup>®</sup> is a registered trademark of Noven Therapeutics, LLC.</content>
                  </paragraph>
                  <paragraph>102086-23</paragraph>
               </text>
               <effectiveTime value="20250523"/>
            </section>
         </component>
         <component>
            <section ID="splSectionMedguide">
               <id root="f01d9e8f-af59-4c28-8807-b09977f8359e"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <table width="100%">
                     <tfoot>
                        <tr styleCode="First Last">
                           <td>
                              <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                           </td>
                           <td/>
                           <td align="right">
                              <paragraph>Revised 06/2025</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3" align="center" valign="middle">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                              <br/>
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">DAYTRANA<sup>®</sup> (day-TRON-ah)</content>
                                 <br/>
                                 <content styleCode="bold">(methylphenidate transdermal system) CII</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">Important: DAYTRANA is for use on the skin only.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">What is the most important information I should know about DAYTRANA?</content>
                              <br/>
                              <paragraph>
                                 <content styleCode="bold">DAYTRANA may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Abuse, misuse, and addiction. </content>DAYTRANA has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of DAYTRANA, other methylphenidate containing medicines, and amphetamine containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of DAYTRANA or when it is used in ways that are not approved, such as snorting or injection.<list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider should check your child's risk for abuse, misuse, and addiction before starting treatment with DAYTRANA and will monitor your child during treatment.</item>
                                       <item>DAYTRANA may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.</item>
                                       <item>Do not give DAYTRANA to anyone else. See "<content styleCode="bold">What is DAYTRANA?</content>" for more information.</item>
                                       <item>Keep DAYTRANA in a safe place and properly dispose of any unused medicine. See "<content styleCode="bold">How should I store DAYTRANA?</content>" for more information.</item>
                                       <item>Tell your healthcare provider if your child has ever abused or been dependent on alcohol, prescription medicines, or street drugs.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Risks for people with serious heart disease.</content> Sudden death has happened in people who have heart defects or other serious heart disease.<br/>Your child's healthcare provider should check your child carefully for blood pressure and heart problems before starting treatment with and while you are using DAYTRANA. Tell your child's healthcare provider if your child has any heart problems, heart disease or heart defects.<br/>
                                    <content styleCode="bold">Remove the DAYTRANA transdermal system (patch) and call your child's healthcare provider or go to the nearest emergency room right away if your child has any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with DAYTRANA.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased blood pressure and heart rate.</content>
                                    <br/>Your child's healthcare provider should check your child's blood pressure and heart rate regularly during treatment with DAYTRANA.</item>
                                 <item>
                                    <content styleCode="bold">Mental (psychiatric) problems, including:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>new or worse behavior or thought problems</item>
                                       <item>new or worse bipolar illness</item>
                                       <item>new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or manic symptoms</item>
                                    </list>Tell your child's healthcare provider about any mental problems your child has or about a family history of suicide, bipolar illness, or depression.<br/>
                                    <content styleCode="bold">Call your child's healthcare provider right away if your child has any new or worsening mental symptoms or problems during treatment with DAYTRANA, especially hearing voices, seeing, or believing things that are not real, or new manic symptoms.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">What Is DAYTRANA?</content>
                              <br/>
                              <paragraph>DAYTRANA is a central nervous system (CNS) stimulant prescription medication used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 to 17 years of age. DAYTRANA may help increase attention and decrease impulsiveness and hyperactivity in children with ADHD.</paragraph>
                              <paragraph>It is not known if DAYTRANA is safe and effective in children younger than 6 years.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">DAYTRANA is a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs. Keep DAYTRANA in a safe place to protect it from theft.</content> Never give your DAYTRANA to anyone else because it may cause death or harm them. Selling or giving away DAYTRANA may harm others and is against the law.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">Do not use DAYTRANA if your child:</content>
                              <list listType="unordered">
                                 <item>is allergic to methylphenidate or any of the ingredients in DAYTRANA. See the end of this Medication Guide for a complete list of ingredients in DAYTRANA.</item>
                                 <item>is taking, or has stopped taking withing the past 14 days, a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">Before using DAYTRANA, tell your child's healthcare provider about all of your child's medical conditions, including if your child:</content>
                              <br/>
                              <list listType="unordered">
                                 <item>has heart problems, heart disease, heart defects, or high blood pressure</item>
                                 <item>has mental problems including psychosis, mania, bipolar illness, or depression, or has a family history of suicide bipolar illness, or depression</item>
                                 <item>has seizures or have had an abnormal brain wave test (EEG)</item>
                                 <item>has circulation problems in fingers or toes</item>
                                 <item>has skin problems such as eczema or psoriasis, or have skin reactions to soaps, lotions, make-up, or adhesives (glues)</item>
                                 <item>has a history of vitiligo or a family history of vitiligo</item>
                                 <item>has eye problems, including increased pressure in your eye, glaucoma, or problems with your close-up vision (farsightedness)</item>
                                 <item>has or had repeated movements or sounds (tics) or Tourettes syndrome, or have a family history of tics or Tourettes syndrome</item>
                                 <item>is pregnant or plans to become pregnant. It is not known if DAYTRANA will harm the unborn baby. Tell your child's healthcare provider if your child becomes pregnant during treatment with DAYTRANA.<list listType="unordered" styleCode="Circle">
                                       <item>There is a pregnancy registry for females who are exposed to DAYTRANA during pregnancy. The purpose of the registry is to collect information about the health of women exposed to DAYTRANA and their baby. If your child becomes pregnant during treatment with DAYTRANA, talk to your child's healthcare provider about registering with the National Pregnancy Registry of Psychostimulants at 1-866-961-2388 or visit online at <linkHtml href="https://womensmentalhealth.org/adhd-medications/">https://womensmentalhealth.org/adhd-medications/</linkHtml>.</item>
                                    </list>
                                 </item>
                                 <item>is breast feeding or plan to breast feed. DAYTRANA passes into breast milk. Talk to your child's healthcare provider about the best way to feed the baby during treatment with DAYTRANA.</item>
                                 <item>a history of vitiligo and/or a family history of vitiligo</item>
                              </list>
                              <content styleCode="bold">Tell your child's healthcare provider about all of the medicines your child takes, </content>including prescription and over-the-counter medicines, vitamins, and herbal supplements.<br/>
                              <paragraph>DAYTRANA and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be changed during treatment with DAYTRANA. Your child's healthcare provider will decide if DAYTRANA can be taken with other medicines.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your child's healthcare provider if your child takes:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>blood pressure medicines (anti-hypertensive)</item>
                              </list>
                              <paragraph>Know the medicines that your child takes. Keep a list of your child's medicines with you to show your child's healthcare provider and pharmacist when your child gets a new medicine. <content styleCode="bold">Do not start any new medicine while using DAYTRANA without first talking to your child's healthcare provider.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">How should DAYTRANA be used?</content>
                              <br/>
                              <list listType="unordered">
                                 <item>See the detailed <content styleCode="bold">“Instructions for Use”</content> at the end of this Medication Guide for information about the right way to apply, remove, and dispose of DAYTRANA.</item>
                                 <item>Use DAYTRANA exactly as prescribed by your child's healthcare provider.</item>
                                 <item>Your child's healthcare provider may change the dose if needed.</item>
                                 <item>Apply DAYTRANA to the hip area 2 hours before an effect is needed and remove DAYTRANA within 9 hours after it is applied. <content styleCode="bold">Do not</content> wear DAYTRANA longer than 9 hours a day.</item>
                                 <item>If DAYTRANA falls off, a new patch may be applied to a different area of the same hip.</item>
                                 <item>If you forget to apply DAYTRANA at your usual scheduled time each day, you may apply the patch later in the day. The patch should be removed at the usual time of day to lower the chance of side effects later in the day.</item>
                                 <item>If your child has loss of appetite or trouble sleeping in the evening, ask your child's healthcare provider if your child can take the patch off earlier in the day.</item>
                                 <item>Contact with water while bathing, swimming, or showering can make the patch not stick well.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use bandages, tape, or other household adhesives (glue) to hold the patch onto the skin.</item>
                              </list>If your child uses too much DAYTRANA transdermal systems call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">What should your child avoid while using DAYTRANA?</content>
                              <br/>
                              <list listType="unordered">
                                 <item>After applying the DAYTRANA patch, avoid exposing the application site to direct external heat sources, such as hair dryers, heating pads, electric blankets, heated water beds or other heat sources. Exposure to heat can cause too much medicine to pass into the body and cause serious side effects.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">What are the possible side effects of DAYTRANA?</content>
                              <paragraph>
                                 <content styleCode="bold">DAYTRANA may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>See <content styleCode="bold">"What is the most important information I should know about DAYTRANA?"</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Seizures.</content> Your child's healthcare provider may stop treatment with DAYTRANA if your child has a seizure.</item>
                                 <item>
                                    <content styleCode="bold">Painful and prolonged erections (priapism).</content> Priapism that may require surgery has happened in people who take products that contain methylphenidate. <content styleCode="bold">If your child develops priapism, get medical help right away.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Circulation problems in fingers and toes (peripheral vasculopathy, including Raynauds phenomenon). Signs and symptoms may include:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>fingers or toes may feel numb, cool, or painful</item>
                                       <item>fingers and toes may change color from pale, to blue, to red</item>
                                    </list>Tell your child's healthcare provider if your child has any numbness, pain, skin color change, or sensitivity to temperature in the fingers or toes.<br/>
                                    <content styleCode="bold">Call your healthcare provider right away if your child has any signs of unexplained wounds appearing on fingers or toes during treatment with DAYTRANA.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Slowing of growth (height and weight) in children.</content> Your child should have their height and weight checked often during treatment with DAYTRANA. Your healthcare provider may stop your child’s DAYTRANA treatment if they are not growing or gaining weight as expected.</item>
                                 <item>
                                    <content styleCode="bold">Eyes problems (increased pressure in the eye and glaucoma).</content> Call your healthcare provider right away if you or your child develop changes in your vision or eye pain, swelling, or redness.</item>
                                 <item>
                                    <content styleCode="bold">New or worsening tics or worsening Tourette's syndrome.</content> Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourettes syndrome during treatment with DAYTRANA.</item>
                                 <item>
                                    <content styleCode="bold">Loss of skin color.</content> DAYTRANA may cause a persistent loss of skin-color where the patch is applied or around the patch application site. Loss of skin-color, in some cases, has been reported at locations on the skin far from any application site. The loss of skin-color may be permanent even after removing the patch or DAYTRANA is stopped. Call your healthcare provider right away if your child has changes in skin-color. DAYTRANA treatment may be stopped if your child has changes in skin color.</item>
                                 <item>
                                    <content styleCode="bold">Allergic skin rash (contact sensitization).</content> Stop using DAYTRANA and tell your child's healthcare provider right away if your child develops swelling or blisters at or around the application site. Your child may have a skin allergy to DAYTRANA. People who have skin allergies to DAYTRANA may develop an allergy to all medicines that contain methylphenidate, even methylphenidate medicines taken by mouth.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">The most common side effects of DAYTRANA in children 6 to 12 years old include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered">
                                 <item>decreased appetite</item>
                                 <item>trouble sleeping</item>
                                 <item>nausea</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>vomiting</item>
                                 <item>weight loss</item>
                                 <item>tics</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <list listType="unordered">
                                 <item>changes in mood</item>
                                 <item>trouble eating</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">The most common side effects of DAYTRANA in children 13 to 17 years old include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered">
                                 <item>decreased appetite</item>
                                 <item>nausea</item>
                                 <item>trouble sleeping</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>weight loss</item>
                                 <item>dizziness</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <list listType="unordered">
                                 <item>stomach pain</item>
                                 <item>trouble eating</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="3">
                              <paragraph>DAYTRANA may also cause skin problems where it is applied (redness, small bumps, itching)</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Your child's doctor may do certain blood tests while your child uses DAYTRANA.</content>
                              </paragraph>
                              <paragraph>These are not all the possible side effects of DAYTRANA.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">How should I store DAYTRANA?</content>
                              <br/>
                              <list listType="unordered">
                                 <item>Store DAYTRANA at room temperature between 68° F to 77° F (20° C to 25° C).</item>
                                 <item>Store DAYTRANA in a safe place, like a locked cabinet.</item>
                                 <item>Do not store DAYTRANA in the refrigerator or freezer.</item>
                                 <item>Keep DAYTRANA in their unopened pouches until you are ready to use them.</item>
                                 <item>Use or throw away the patches within 2 months after you open the sealed tray.</item>
                                 <item>Dispose of remaining, unused, or expired DAYTRANA by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, each unused patch should be removed from its individual pouch, separated from the protective liner, folded in half so that the sticky sides stick together, and flushed down the toilet. Put the pouch and liner in a container with a lid, close the container and throw away the container in the household trash. Do not flush the pouch and liner down the toilet. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</item>
                              </list>
                              <content styleCode="bold">Keep DAYTRANA and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of DAYTRANA.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use DAYTRANA for a condition for which it was not prescribed. Do not give DAYTRANA to other people, even if they have the same symptoms. It may harm them and it is against the law.</paragraph>
                              <paragraph>You can ask your pharmacist or healthcare provider for information about DAYTRANA that is written for healthcare professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="3">
                              <content styleCode="bold">What are the ingredients in DAYTRANA?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> methylphenidate<br/>
                              <content styleCode="bold">Inactive ingredients: </content>acrylic adhesive, silicone adhesive<br/>
                              <paragraph>Manufactured by: Noven Pharmaceuticals, Inc., Miami, FL 33186<br/>DAYTRANA<sup>®</sup> is a trademark of Noven Therapeutics, LLC.</paragraph>
                              <paragraph>For more information, go to www.daytrana.com, or call 1-800-455-8070.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250527"/>
            </section>
         </component>
         <component>
            <section ID="VP300">
               <id root="ae4e7c4a-257f-43d6-9856-2943aefd9b75"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <table width="100%">
                     <tbody>
                        <tr styleCode="First Last">
                           <td align="center">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              <br/>
                              <content styleCode="bold">DAYTRANA<sup>®</sup> (day-TRON-ah)</content>
                              <br/>
                              <content styleCode="bold">(methylphenidate transdermal system) CII</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">1. DAYTRANA Dosing Chart</content>
                  </paragraph>
                  <paragraph>Each carton of DAYTRANA contains a DAYTRANA Dosing Chart to help you keep track of your DAYTRANA transdermal system (patch) including:</paragraph>
                  <list listType="unordered">
                     <item>when you apply patch to the skin on your hip each morning</item>
                     <item>when you remove the patch</item>
                     <item>how and where you threw DAYTRANA away</item>
                  </list>
                  <paragraph>To use the DAYTRANA Dosing Chart, follow these instructions:</paragraph>
                  <list listType="unordered">
                     <item>Each day, when a new patch is applied to your hip, write down the date and time that you applied the patch.</item>
                     <item>Use the DAYTRANA schedule below so you can decide when to remove the patch. For example, if the patch is applied to the skin at 6:00 a.m., remove the patch at 3:00 p.m. on the same day. After you remove and throw away the patch, write down the time you removed the patch and how and where you threw it away.</item>
                     <item>If the patch you placed on your child is missing, ask your child:<list listType="unordered">
                           <item>when the patch came off</item>
                           <item>how the patch came off</item>
                           <item>where the patch is</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">DAYTRANA Schedule for 9 Hour Dosing</content>
                  </paragraph>
                  <table ID="i225c6d0c-2dda-49e1-8fd9-b1016b35d8d3" width="700px">
                     <colgroup>
                        <col width="50%" align="left"/>
                        <col width="50%" align="left"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold">If you put the patch on at:</content>
                           </td>
                           <td styleCode="Botrule" align="left" valign="top">
                              <content styleCode="bold">On the same day, remove the patch at:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left">5:00 a.m.</td>
                           <td styleCode="Botrule" align="left">2:00 p.m.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left">6:00 a.m.</td>
                           <td styleCode="Botrule" align="left">3:00 p.m.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left">7:00 a.m.</td>
                           <td styleCode="Botrule" align="left">4:00 p.m.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left">8:00 a.m.</td>
                           <td styleCode="Botrule" align="left">5:00 p.m.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left">9:00 a.m.</td>
                           <td styleCode="Botrule" align="left">6:00 p.m.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left">10:00 a.m.</td>
                           <td styleCode="Botrule" align="left">7:00 p.m.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left">11:00 a.m.</td>
                           <td styleCode="Botrule" align="left">8:00 p.m.</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" align="left">12:00 p.m.</td>
                           <td styleCode="Botrule" align="left">9:00 p.m.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">2. Where to apply DAYTRANA</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Apply patch to your hip area. Do not put the patch near your waist. Clothing and movement may make your patch rub off (See Figure A).</item>
                     <item>Use your other hip when you apply a new patch the next morning. Make sure there is no redness, small bumps or itching at the site where the patch is going to be applied.</item>
                  </list>
                  <renderMultiMedia referencedObject="L94e53fb1-e68b-43eb-83f1-426f69ba12c7"/>
                  <content styleCode="bold">Figure A </content>
                  <paragraph>
                     <content styleCode="bold">3.  Before you apply DAYTRANA </content>
                  </paragraph>
                  <paragraph>Make sure your skin:</paragraph>
                  <list listType="unordered">
                     <item>Is clean (freshly washed), dry, and cool</item>
                     <item>Does not have any powder, oil, or lotion</item>
                     <item>Does not have any cuts and irritation (rashes, inflammation, redness, or other skin problems).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">4</content>. <content styleCode="bold"> How to apply DAYTRANA</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Open the sealed tray and throw away the small packet (drying agent).</item>
                     <item>Each patch is sealed in its own protective pouch.</item>
                     <item>Carefully cut the protective pouch open with scissors, being careful not to cut the patch. <content styleCode="bold">Do not use patches that have been cut or damaged in any way (See Figure B).</content>
                     </item>
                  </list>
                  <content styleCode="bold">
                     <renderMultiMedia referencedObject="Lfd39dca1-d800-43d1-ab62-e80c7e1759fb"/>
                  </content>
                  <paragraph>
                     <content styleCode="bold">Figure B</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Remove the patch from the protective pouch.</item>
                     <item>Look at the patch to make sure it is not damaged. The patch should separate easily from the protective liner. Throw away the patch if the protective liner is hard to remove.</item>
                  </list>
                  <paragraph>DAYTRANA has 3 layers. The 3 layers are pictured below. The pictures show both sides of the patch: </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Le25c4749-1565-4924-aa31-2feee0b6279c"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">                         Figure C                                                                  Figure D</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Layers:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Protective liner:</content> The protective liner is the layer that you remove before you put the patch on (See Figure C).</item>
                     <item>
                        <content styleCode="bold">Adhesive with medicine:</content> The adhesive with medicine is the layer that sticks to your skin (See Figure C).</item>
                     <item>
                        <content styleCode="bold">Outside backing:</content> The outside backing is the layer that you see after you put the patch on your skin. The word "Daytrana" is printed on this layer (See Figure D).</item>
                  </list>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Apply the patch right away after you remove the patch from protective pouch</content>.</item>
                     <item>Hold the patch with the hard protective liner facing you. The word DAYTRANA will appear backwards.</item>
                     <item>
                        <content styleCode="bold">Gently</content> bend the patch along the faint line and <content styleCode="bold">slowly peel</content> half the liner, which covers the sticky surface of the patch (See Figure E).</item>
                  </list>
                  <renderMultiMedia referencedObject="L282cc265-bff8-49c5-a931-1c3f0faff1a4"/>
                  <paragraph>
                     <content styleCode="bold">Figure E</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Avoid touching the sticky side of the patch with your fingers.</item>
                     <item>If you accidentally touch the sticky side of the patch, apply the patch, then wash your hands right away so that the medicine does not go into the skin on your hands.</item>
                     <item>Using the other half of the protective liner as a handle, apply the sticky side of the patch to the selected area of the child's hip (See Figure F).</item>
                  </list>
                  <renderMultiMedia referencedObject="Le55d28ba-5045-49e7-995d-ddc3513aa6d5"/>
                  <paragraph>
                     <content styleCode="bold">Figure F</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Press the sticky side of the patch firmly into place and smooth it down.</item>
                     <item>While you are still holding the sticky side down, gently fold back the other half of the patch.</item>
                     <item>Hold an edge of the remaining protective liner and <content styleCode="bold">slowly peel</content> it off (See Figure G).</item>
                  </list>
                  <renderMultiMedia referencedObject="Lb6c7e73f-5103-4229-ad51-12f8f6dc9830"/>
                  <paragraph>
                     <content styleCode="bold">Figure G</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>After the protective liner is removed, there should not be any adhesive (glue) sticking to the liner.</item>
                  </list>
                  <renderMultiMedia referencedObject="L5185800c-d4f5-4de7-8053-226b90f4bd63"/>
                  <paragraph>
                     <content styleCode="bold">Figure H</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Press the entire patch firmly into place with the palm of your hand over the patch for about 30 seconds (See Figure H).</content>
                     </item>
                     <item>Make sure that the patch firmly sticks to your skin.</item>
                     <item>Gently rub the edges of the patch with your fingers to make sure the patch sticks to your skin.</item>
                     <item>Wash your hands after you apply your patch.</item>
                     <item>Write the time you applied your patch on the dosing chart on the carton. Use the dosing schedule so you know what time you should remove your patch.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">5. How to remove and throw away DAYTRANA</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>When you remove the patch, peel it off slowly. If the patch is too sticky on your skin and you need something to help you remove it:<list listType="unordered">
                           <item>Gently apply an oil-based product (petroleum jelly, olive oil, or mineral oil) to the patch edges. Gently spread the oil underneath the patch edges.</item>
                           <item>Apply an oil-based product or lotion to your skin if any adhesive (glue) remains after you remove your patch. This will gently loosen and remove any adhesive that is left over.</item>
                           <item>If you still cannot easily remove the patch, ask your doctor or pharmacist about what to do for this problem.</item>
                        </list>
                     </item>
                     <item>Fold the used patch in half and press it together firmly so that the sticky side sticks to itself. <content styleCode="bold">Flush the used patch down the toilet.</content>
                     </item>
                     <item>Do not flush the protective pouches or the protective liners down the toilet. These items should be thrown away in a container with a lid.</item>
                     <item>Wash your hands after you handle the patch.</item>
                     <item>After you remove the patch and throw the patch away, write down the time on the dosing chart.</item>
                     <item>Safely throw away any unused patches that are left over from the prescription as soon as they are no longer needed. <br/>To safely throw away the patches:<list listType="unordered">
                           <item>Remove the leftover patches from their protective pouches and remove the protective liners.</item>
                           <item>Either fold the patches in half with the sticky sides together, and flush the patches down the toilet, <content styleCode="bold">or</content>
                           </item>
                           <item>Dispose of remaining, unused, or expired DAYTRANA by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, each unused patch should be removed from its individual pouch, separated from the protective liner, folded in half so that the sticky sides stick together, and flushed down the toilet. Put the pouch and liner in a container with a lid, close the container and throw away the container in the household trash. Do not flush the pouch and liner down the toilet. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>Manufactured for: Noven Therapeutics, LLC, Miami, FL 33186.</paragraph>
                  <paragraph>By: Noven Pharmaceuticals, Inc., Miami, FL 33186.<br/>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: 06/2025</paragraph>
                  <paragraph>102086-23</paragraph>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <observationMedia ID="L94e53fb1-e68b-43eb-83f1-426f69ba12c7">
                     <text>daytrana-ppi-fig1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lfd39dca1-d800-43d1-ab62-e80c7e1759fb">
                     <text>daytrana-ppi-fig2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Le25c4749-1565-4924-aa31-2feee0b6279c">
                     <text>daytrana-patch</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L282cc265-bff8-49c5-a931-1c3f0faff1a4">
                     <text>daytrana-ppi-fig3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Le55d28ba-5045-49e7-995d-ddc3513aa6d5">
                     <text>daytrana-ppi-fig4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lb6c7e73f-5103-4229-ad51-12f8f6dc9830">
                     <text>daytrana-ppi-fig5</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L5185800c-d4f5-4de7-8053-226b90f4bd63">
                     <text>daytrana-ppi-fig6</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPDP">
               <id root="c53b4cff-fdce-476a-b22f-9f11bf95f499"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - NDC 68968-5552-3 - 10 mg 30 Count Carton</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L5486fafe-f809-4558-bd44-fc607059b35c"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 68968-5552-3</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Daytrana<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(methylphenidate transdermal system)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Delivers 10 mg over 9 hours</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(1.1 mg/hr)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Patch should be worn for approximately 9 hours</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Contains: 30 Patches</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Noven Therapeutics, LLC</paragraph>
                  <paragraph>
                     <content styleCode="bold">Once the tray is opened, use contents within 2 months.</content>
                  </paragraph>
                  <paragraph>Manufactured for Noven Therapeutics, LLC, Miami, FL 33186</paragraph>
                  <paragraph>By Noven Pharmaceuticals, Inc.</paragraph>
                  <paragraph>©2007, 2010 Noven Pharmaceuticals, Inc.</paragraph>
                  <paragraph>1-877-567-7857</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmacists: Enclosed Medication Guide to be dispensed to each patient.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">302188-8 Rev. 9/2016</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each patch contains 27.5 mg of methylphenidate.</content>
                  </paragraph>
                  <paragraph>Active ingredient release is limited; please see recommended dosing in patient instructions.</paragraph>
                  <paragraph>Inactive components: acrylic adhesive, coextruded backing film, polyester release liner and silicone adhesive.</paragraph>
                  <paragraph>For transdermal use only (applied only to skin).</paragraph>
                  <paragraph>Keep all patches within provided containers and dispense one patch daily. Apply immediately upon removal from pouch.</paragraph>
                  <paragraph>Do not store unpouched. Do not store patches in refrigerators or freezers.</paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP controlled Room Temperature]</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important: Keep out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">It is important that this product be disposed of properly. See patient instructions for disposal information.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage and Administration:</content> See package insert.</paragraph>
                  <table width="100%">
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Rrule" align="center">
                              <paragraph>Date of Patch Application</paragraph>
                              <paragraph>MM/DD/YYYY</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Applied</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Removed</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Application Side</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Disposal Method</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Date of Patch Application<paragraph>MM/DD/YYYY</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Applied </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Removed </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Application Side </td>
                           <td styleCode="Botrule Lrule" align="center">Disposal Method </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <observationMedia ID="L5486fafe-f809-4558-bd44-fc607059b35c">
                     <text>daytrana-10mg-30ct-carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPDP2">
               <id root="06dda7ab-c67e-477d-a2f3-06022afa19ab"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - NDC 68968-5553-3 - 15 mg 30 Count Carton</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L5d57a7c1-e156-45f6-985b-21234ce03f05"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 68968-5553-3</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Daytrana<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(methylphenidate transdermal system)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Delivers 15 mg over 9 hours</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(1.6 mg/hr)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Patch should be worn for approximately 9 hours</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Contains: 30 Patches</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Noven Therapeutics, LLC</paragraph>
                  <paragraph>
                     <content styleCode="bold">Once the tray is opened, use contents within 2 months.</content>
                  </paragraph>
                  <paragraph>Manufactured for Noven Therapeutics, LLC, Miami, FL 33186</paragraph>
                  <paragraph>By Noven Pharmaceuticals, Inc.</paragraph>
                  <paragraph>©2007, 2010 Noven Pharmaceuticals, Inc.</paragraph>
                  <paragraph>1-877-567-7857</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmacists: Enclosed Medication Guide to be dispensed to each patient.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">302189-8 Rev. 9/2016</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each patch contains 41.3 mg of methylphenidate.</content>
                  </paragraph>
                  <paragraph>Active ingredient release is limited; please see recommended dosing in patient instructions.</paragraph>
                  <paragraph>Inactive components: acrylic adhesive, coextruded backing film, polyester release liner and silicone adhesive.</paragraph>
                  <paragraph>For transdermal use only (applied only to skin).</paragraph>
                  <paragraph>Keep all patches within provided containers and dispense one patch daily. Apply immediately upon removal from pouch.</paragraph>
                  <paragraph>Do not store unpouched. Do not store patches in refrigerators or freezers.</paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP controlled Room Temperature]</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important: Keep out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">It is important that this product be disposed of properly. See patient instructions for disposal information.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage and Administration:</content> See package insert.</paragraph>
                  <table width="100%">
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Rrule" align="center">
                              <paragraph>Date of Patch Application</paragraph>
                              <paragraph>MM/DD/YYYY</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Applied</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Removed</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Application Side</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Disposal Method</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Date of Patch Application<paragraph>MM/DD/YYYY</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Applied </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Removed </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Application Side </td>
                           <td styleCode="Botrule Lrule" align="center">Disposal Method </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <observationMedia ID="L5d57a7c1-e156-45f6-985b-21234ce03f05">
                     <text>daytrana-15mg-30ct-carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPDP3">
               <id root="69e4ca15-6e48-4861-899d-2adefef7a0f5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - NDC 68968-5554-3 - 20 mg 30 Count Carton</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L3e538bde-9d7d-4c56-a061-298dbde60d62"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 68968-5554-3</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Daytrana<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(methylphenidate transdermal system)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Delivers 20 mg over 9 hours</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(2.2 mg/hr)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Patch should be worn for approximately 9 hours</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Contains: 30 Patches</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Noven Therapeutics, LLC</paragraph>
                  <paragraph>
                     <content styleCode="bold">Once the tray is opened, use contents within 2 months.</content>
                  </paragraph>
                  <paragraph>Manufactured for Noven Therapeutics, LLC, Miami, FL 33186</paragraph>
                  <paragraph>By Noven Pharmaceuticals, Inc.</paragraph>
                  <paragraph>©2007, 2010 Noven Pharmaceuticals, Inc.</paragraph>
                  <paragraph>1-877-567-7857</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmacists: Enclosed Medication Guide to be dispensed to each patient.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">302190-8 Rev. 9/2016</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each patch contains 55 mg of methylphenidate.</content>
                  </paragraph>
                  <paragraph>Active ingredient release is limited; please see recommended dosing in patient instructions.</paragraph>
                  <paragraph>Inactive components: acrylic adhesive, coextruded backing film, polyester release liner and silicone adhesive.</paragraph>
                  <paragraph>For transdermal use only (applied only to skin).</paragraph>
                  <paragraph>Keep all patches within provided containers and dispense one patch daily. Apply immediately upon removal from pouch.</paragraph>
                  <paragraph>Do not store unpouched. Do not store patches in refrigerators or freezers.</paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP controlled Room Temperature]</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important: Keep out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">It is important that this product be disposed of properly. See patient instructions for disposal information.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage and Administration:</content> See package insert.</paragraph>
                  <table width="100%">
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Rrule" align="center">
                              <paragraph>Date of Patch Application</paragraph>
                              <paragraph>MM/DD/YYYY</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Applied</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Removed</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Application Side</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Disposal Method</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Date of Patch Application<paragraph>MM/DD/YYYY</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Applied </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Removed </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Application Side </td>
                           <td styleCode="Botrule Lrule" align="center">Disposal Method </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <observationMedia ID="L3e538bde-9d7d-4c56-a061-298dbde60d62">
                     <text>daytrana-20mg-30ct-carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="splSectionPDP4">
               <id root="21b2c940-4bc5-47d3-9843-ba2670364dc4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - NDC 68968-5555-3 - 30 mg 30 Count Carton</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Lc4437745-48c4-486c-97b8-6dea50d2f404"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 68968-5555-3</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Daytrana<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(methylphenidate transdermal system)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Delivers 30 mg over 9 hours</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(3.3 mg/hr)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Patch should be worn for approximately 9 hours</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Contains: 30 Patches</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Noven Therapeutics, LLC</paragraph>
                  <paragraph>
                     <content styleCode="bold">Once the tray is opened, use contents within 2 months.</content>
                  </paragraph>
                  <paragraph>Manufactured for Noven Therapeutics, LLC, Miami, FL 33186</paragraph>
                  <paragraph>By Noven Pharmaceuticals, Inc.</paragraph>
                  <paragraph>©2007, 2010 Noven Pharmaceuticals, Inc.</paragraph>
                  <paragraph>1-877-567-7857</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmacists: Enclosed Medication Guide to be dispensed to each patient.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">302191-8 Rev. 9/2016</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each patch contains 82.5 mg of methylphenidate.</content>
                  </paragraph>
                  <paragraph>Active ingredient release is limited; please see recommended dosing in patient instructions.</paragraph>
                  <paragraph>Inactive components: acrylic adhesive, coextruded backing film, polyester release liner and silicone adhesive.</paragraph>
                  <paragraph>For transdermal use only (applied only to skin).</paragraph>
                  <paragraph>Keep all patches within provided containers and dispense one patch daily. Apply immediately upon removal from pouch.</paragraph>
                  <paragraph>Do not store unpouched. Do not store patches in refrigerators or freezers.</paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP controlled Room Temperature]</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important: Keep out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">It is important that this product be disposed of properly. See patient instructions for disposal information.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage and Administration:</content> See package insert.</paragraph>
                  <table width="100%">
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Rrule" align="center">
                              <paragraph>Date of Patch Application</paragraph>
                              <paragraph>MM/DD/YYYY</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Applied</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Removed</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Application Side</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Disposal Method</td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Date of Patch Application<paragraph>MM/DD/YYYY</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Applied </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Time Removed </td>
                           <td styleCode="Botrule Lrule Rrule" align="center">Application Side </td>
                           <td styleCode="Botrule Lrule" align="center">Disposal Method </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="right">
                              <paragraph>_Fold &amp; flush</paragraph>
                              <paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _AM _PM</td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center"> _Right _Left</td>
                           <td styleCode="Botrule Lrule Toprule" align="right">_Fold &amp; flush<paragraph>_ Fold &amp; trash</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <observationMedia ID="Lc4437745-48c4-486c-97b8-6dea50d2f404">
                     <text>daytrana-30mg-30ct-carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="daytrana-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>